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ABSTRACT OF DISSERTATION

ASSOCIATIONS BETWEEN PSYCHOSOCIAL STRESSORS, GENES, AND
CARDIOVASCULAR DISEASE IN AT-RISK ADULTS
Psychosocial stressors have a significant adverse impact on cardiovascular health.
While better medical treatments and increased emphasis on healthy lifestyle have
improved cardiovascular health for many in the United States over the past 50 years,
there are persistent inequities in cardiovascular disease (CVD) rates, with the highest
rates among populations burdened by chronic exposure to psychosocial stressors such as
discrimination and anxiety, among others. Genetic factors may interact with these
stressors further influencing the rates of CVD in these populations. The purpose of this
dissertation is to examine associations among psychosocial stressors and other CVD risk
factors, and the influence of genetic variations on these associations in populations
burdened with significant cardiovascular health inequities. Specific aims of this
dissertation were to: (1) systematically review instruments measuring ethnic
discrimination in Hispanic populations; (2) examine the association between
psychosocial stressors and other CVD risk factors in adults with a high burden of health
disparities who are at-risk for CVD; and (3) explore the moderation effect of genetic
variants on the relationships between psychosocial stressors and CVD risk factors.
This dissertation includes three original manuscripts. The first specific aim was
addressed by the first paper which is a systematic review of psychometrically tested
instruments used to measure ethnic discrimination is Hispanic adults. Six instruments
were reviewed. Of these, the “Experiences of Discrimination” instrument, available in
both English and Spanish, was a valid and reliable instrument that provided the most
concise measure of lifetime experiences of ethnic discrimination in Hispanic adults.
Specific aims two and three were addressed by the second and third papers. The second
paper was a secondary analysis of data examining the association between anxiety and
inflammation, and the moderation of this relationship by single nucleotide
polymorphisms (SNPs) associated with systemic inflammation, including rs1205,
rs1800797, and rs4129267, located on the CRP gene, IL-6 gene, and IL-6R gene,
respectively. Findings revealed that only the IL-6R SNP, rs4129267, moderated the

association between anxiety and inflammation. In the final paper, results are reported
from a study conducted to assess whether experiences of ethnic discrimination predict
depressive symptoms in Hispanic adults, and to examine if a SNP on the COMT
(catechol-o-methyltransferase) gene moderated this relationship. Results revealed that
experiences of ethnic discrimination and COMT genotype are independently associated
with increased depressive symptoms.
The findings from the studies conducted for this dissertation suggest that
addressing psychosocial stressors such as experiences of discrimination and anxiety is
critical to cardiovascular health promotion. Further, the results provide preliminary
evidence of moderating effects of genetic variants on associations between psychosocial
stressors and CVD risk. These findings fill an important gap in the body of knowledge
related to CVD inequities in populations burdened by psychosocial stressors. Further
research is needed to better understand the effects of such stressors as experiences of
discrimination on CVD and genetic variants explore the unique experiences of these
populations which may affect their CVD risk, as well as exploration into how best
integrate genetics into CVD prevention efforts to maximize the impact of interventions.
KEYWORDS: cardiovascular disease,
inflammation, depressive symptoms
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INTRODUCTION
1.1

Cardiovascular Disease Risk
Cardiovascular disease (CVD) is the leading cause of death globally.1 In 2016, CVD

accounted for over 17.6 million deaths worldwide, and is expected to account for over
23.6 million deaths by the year 2030.1 In the United States (U.S.), CVD is present in 48%
of adults aged 20 years or older, and causes 1 in 3 deaths nationally.1 For many in the
U.S., however, better medical treatments and increased emphasis on healthy lifestyle
have significantly improved cardiovascular health over the past 50 years. Notably,
though, these improvements do not uniformly impact all, resulting in disparately higher
rates of CVD in certain U.S. populations.
Among those most adversely affected by high rates of CVD are rural-dwelling
adults.2,3 Across the nation, rural-dwelling adults experience higher CVD rates than
urban-dwelling adults. A recent analysis of 2014 National Vital Statistics System
mortality data showed that for adults less than 80 years of age, 42.6% of deaths due to
heart disease in rural areas were in excess of what would have been expected compared
with only 27.8% in non-rural areas.4
Notably, rural Kentucky adults have significantly higher rates of CVD than other U.S.
communities, whether rural or urban. A report of 2014 cardiovascular death rates across
U.S. counties showed the highest rates of CVD in the rural counties of Eastern
Kentucky.5 This is unsurprising given that among rural Kentucky adults, there are
significantly higher rates of tobacco use,6 physical inactivity,7 obesity,8 poor dietary
patterns,7 and hypertension9 compared with the general population, placing this
population at higher risk for CVD. Further adding to the rural Kentuckians’ CVD risk is
1

the rural environment in which this population lives, and the unique stressors that may
arise from this environment, such as lack of access to medical care, lack of access to
healthy lifestyle resources, and high levels of poverty.9,10 Downstream effects of these
stressors may include increased anxiety levels or symptoms of depression, and in turn,
further increased CVD risk.
Similar to rural populations, racial and ethnic minorities in the U.S. carry a heavier
burden of CVD morbidity and mortality. For example, African Americans and Native
Americans have among the highest rates of CVD risk factors, such as obesity, type 2
diabetes, and hypertension, leading to disproportionate rates of CVD and CVD-related
deaths.11,12 Hispanic adults are also at increased risk for CVD due to the high rates of
CVD risk factors also seen in this population. Compared to non-Hispanic white adults in
the U.S., Hispanic adults have higher levels of obesity, physical inactivity,
hypercholesterolemia, and diabetes.13 Hispanics also experience psychosocial stressors
similar to those experienced by rural Kentucky adults, such as lack of access to medical
services and higher levels of poverty, which increases CVD risk.14 However, Hispanics
also experience other psychosocial stressors, such as ethnic discrimination, which are
more unique to their population and may also worsen their CVD risk.15 The high
prevalence of traditional behavioral CVD risk factors, coupled with the psychosocial
stressors experienced by this population, could further exacerbate the already high CVD
risk in Hispanic adults.

1.2

Psychosocial Stressors and Cardiovascular Disease Risk
Preventing CVD remains a major challenge especially in high-risk populations

including in rural and Hispanic adults. While multiple factors are known to influence risk
2

in these populations, psychosocial stressors may be particularly significant contributors,
although the stressors experienced in each community may be unique. In this dissertation,
associations between the effects of psychosocial stressors unique to each population and
CVD risk will be examined.
Ethnic discrimination is a notable psychosocial stressor experienced by U.S. Hispanic
communities. This stressor results from negative transactions between ethnic minority
individuals or groups and their environment that exceed coping resources or threaten the
well-being of the individual or group.16-18 Ethnic discrimination as defined by Clark and
colleagues are the “beliefs, attitudes, institutional arrangements, and acts that denigrate
individuals or groups because of phenotypic characteristics or ethnic group affiliation.”19
Considering this, some have hypothesized that stress responses such as hormonal
dysregulation,20 cellular aging,21 and changes to allostatic load may influence health
outcomes in the presence of discrimination-related stress.16,22 Further, given the
pervasiveness of ethnic discrimination across many areas of life, and given that
experiences of discrimination accumulate over a person’s lifetime, ethnic discrimination
is a key contributor to chronic stress. Unlike the brief disruption to allostasis and rapid
return to pre-stress equilibrium associated with acute stress, with chronic stress, the
continuously activated stress response adversely impacts both physical and mental
health.23-25
There are many types of racial and ethnic discrimination, ranging from insults and
racial slurs to denial of equal treatment and acts of violence against those who are racial
and ethnic minorities.26 In the U.S., nearly 70% of Hispanic adults report personal
experiences of ethnic discrimination during their lifetime.27 These experiences occur in a

3

variety of situations including when seeking employment, in interactions with authorities,
when seeking health care services, and in interpersonal interactions.27,28 In Hispanic
individuals, experienced ethnic discrimination has been consistently associated with
negative health outcomes, including negative mental health outcomes.15 Specifically,
experiences of discrimination have been linked to increases in CVD risk factors such as
hypertension, systemic inflammation, anxiety, and depression.29-32
Anxiety is another example of a stressor associated with increased CVD risk that may
be experienced by the two populations of interest in this dissertation. Higher levels of
anxiety have been demonstrated to be associated with increased risk for CVD in
otherwise healthy individuals.33 There are several proposed mechanisms through which
anxiety is thought to be associated with increased CVD risk. Among the proposed
mechanisms is a link between high anxiety and unhealthy lifestyle behaviors that, in turn,
increase CVD risk.34 Others have reported that CVD risk is increased in individuals with
high anxiety due to over-activation of both the sympathetic nervous system and the
hypothalamic-pituitary-adrenal axis, which can lead to increased plasma catecholamine
levels, resulting in endothelial damage, atherosclerosis, and coronary artery disease.34 A
final proposed mechanism suggests that anxiety may increase CVD risk through
inflammatory pathways.35,36
Similar to anxiety, depression is a mental health condition that is associated with
increased CVD risk.37 Although the etiology is not well understood, it is commonly
accepted that depression is influenced by a combination of environmental, physiological,
psychosocial, and genetic factors. For example, in addition to psychosocial influences,
such as ethnic discrimination, prevailing physiological theories support that depression

4

may be due to monoamine neurotransmission system dysfunction that leads to decreased
levels of monoamine neurotransmitters such as serotonin and dopamine.38 Serotonin is
currently thought to be associated with depressive symptoms through low serotonin
function resulting from tryptophan depletion, the precursor amino acid to serotonin.39
Dopamine, another monoamine neurotransmitter, has been found to have a key role in
motivation and salience,40 and abnormal dopamine levels have been associated with
depressive symptoms such as anhedonia, disrupted sleep, and decreased motivation.41

1.3

The Influence of Genes on Cardiovascular Disease Risk Factors
Traditionally, CVD prevention efforts have focused primarily on behavioral,

environmental, and psychosocial factors which place individuals at increased risk for
CVD. However, more recently, there has been increasing evidence genetic influences
associated with CVD risk, and research has been focused on identifying genetic variants
that are associated with the development of CVD.42 Genetic variants, including single
nucleotide polymorphisms (SNPs), have been linked to increased CVD risk through the
association with CVD risk factors, such as hypertension,42 increased levels of
inflammatory biomarkers,43,44 and increased depressive symptoms.45
Depression is a known risk factor for CVD.37,46,47 There is also growing evidence that
there is a genetic component to depression. For example, in a twin study examining both
monozygotic and dizygotic twins, results indicate that the heritability of depression may
be as high as 38%.48 Results from family studies suggest there is up to a threefold
increase in lifetime risk of depression among first-degree relatives of persons with
depression.49 Considering that abnormal levels of monoamine neurotransmitters, such as
serotonin and dopamine, are thought to be associated with the development of depression,
5

genes within the dopaminergic neurotransmission system, such as the catechol-omethyltransferase (COMT) gene, have frequently been targeted in investigations of the
genetic predisposition for depressive symptoms.
Similarly, increased levels of systemic inflammation have been associated with
increased development of CVD.50,51 Although behavioral factors,52 such as physical
activity and diet quality, and psychosocial stressors, such as anxiety,36 are associated with
levels of inflammation, inflammation is also known to have a strong genetic
component.43 Several common SNPs, located within or near inflammatory response
genes, including several interleukin variants, have been shown to be associated with
increased levels of circulating inflammatory biomarker proteins, particularly when a SNP
resides within a key regulatory region of the gene.44,53

1.4

Interactions between Genes, Stress, and Cardiovascular Disease Risk
Although considering genetic variants associated with CVD risk factors may help

further our understanding of CVD risk, genetic variants are not solely responsible for the
development of CVD. Rather, genetic variants should be considered within the context of
other known CVD risk factors. An example of this is examining interactions among CVD
risk factors and genetic variants, as interactions among CVD risk factors have been
recognized as an important part of CVD etiology.54 In populations, such as Hispanics and
rural Kentucky adults, with known cardiovascular health inequities, genes associated with
CVD risk factors may further exacerbate existing inequities.
The identification of interactions among genetic variants and CVD risk factors, such
as psychosocial stressors, should be of importance in the populations with disparate rates
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of CVD. Better understanding and clarification of these relationships and interactions
among CVD risk factors and genes would add to the knowledge of the etiology of CVD
and provide evidence to support identification and implementation of early prevention
strategies for those most vulnerable to the development of CVD.

1.5

Purpose of Dissertation
The purpose of this dissertation is to examine associations between psychosocial

stressors and CVD risk factors, and the influence of genes on these associations in
populations burdened with significant CVD health disparities. The specific aims of this
dissertation were to: (1) systematically review instruments measuring ethnic
discrimination in Hispanic populations, (2) examine the association between psychosocial
stressors and CVD risk factors, and (3) explore the moderation effect of genetic variants
on the relationships between psychosocial stressors and CVD risk factors.

1.6

Summary of Subsequent Chapters
Chapter 2 presents a systematic review of instruments measuring ethnic

discrimination in Hispanic adults. An electronic search of PubMed, PsychInfo, and
Sociological Abstracts was conducted. Keywords were “discrimination”, “Hispanic”,
“Latino”, “measurement”, “racial discrimination”, and “ethnic discrimination.” After
applying inclusion and exclusion criteria, 16 articles were included in this review, from
which six measures of ethnic discrimination were identified. Instruments varied in
number of items, constructs measured, and timing of discrimination experiences. For
example, in contrast to the 9-item “Experiences of Discrimination” (EOD) scale that
measures in how many situations and how often discrimination is experienced, the 707

item “Perceived Ethnic Discrimination Questionnaire” includes 5 subscales and assesses
lifetime and past-week discrimination experiences. The reliability and validity of all
instruments was assessed. The conclusions drawn from this review guided the selection
of the instrument used to measure experiences of ethnic discrimination in the study
described in chapter four of this dissertation.
Chapter 3 presents a secondary analysis of data examining the relationship between
anxiety and systemic inflammation in individuals at risk for CVD, and whether SNPs
associated with inflammation moderate this relationship. A total of 398 adults residing in
rural Kentucky participated in this study. Anxiety was measured using the Brief
Symptom Inventory. Protein levels for C-reactive protein (CRP) and interleukin-6 (IL-6)
were measured in serum, and genomic DNA was assayed for SNPs in the CRP, IL-6, and
IL6R genes. Hierarchical multiple linear regressions were performed to examine if
anxiety predicted inflammation (as measured by CRP and IL-6), and if SNPs moderated
these associations.
Chapter 4 presents findings from a genetics sub-study that was leveraged on the
“Corazón de la Familia” study. The sample consisted of 124 community-dwelling
Hispanic adults. This study was conducted to investigate the effects of ethnic
discrimination-related stress and a SNP on the catechol-o-methyltransferase (COMT)
gene on symptoms of depression in Hispanic adults at risk for CVD. Cross-sectional data
were analyzed to examine the relationship between lifetime experiences of ethnic
discrimination and depressive symptoms; between Val158Met SNP and depressive
symptoms; and to explore the moderating effect of Val158Met SNP on the association
between discrimination and depressive symptoms in Hispanic adults. Ethnic
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discrimination was measured using the Experiences of Discrimination instrument, and the
Patient Health Questionnaire-8 (PHQ-8) was used to assess depressive symptoms.
Genomic DNA isolated from saliva samples was assayed for a SNP in the COMT gene. A
hierarchical multiple linear regression was performed to examine if experiences of ethnic
discrimination and the Val158Met polymorphism predicted depressive symptoms, as well
as to examine if the Val158Met polymorphism moderated the relationship between
experiences of discrimination and depressive symptoms.
Chapter 5 is an integrated discussion based on the findings of the three studies
presented in this dissertation. This chapter synthesizes how psychosocial stress, and
genes impact CVD risk in populations that suffer from significant health inequities, and
how these findings address the current gaps in the literature. Lastly, implications for
nursing practice and future directions for research in these populations are proposed.

9

SYSTEMATIC REVIEW OF THE VALIDITY AND RELIABILITY OF
INSTRUMENTS MEASURING ETHNIC DISCRIMINATION IN HISPANIC
ADULTS
2.1

Introduction
In the United States (U.S.), racial and ethnic discrimination is a prevalent and

pervasive problem for those belonging to minority groups. Discrimination, as defined by
Clark and colleagues (1999), consists of the “beliefs, attitudes, institutional arrangements,
and acts that denigrate individuals or groups because of phenotypic characteristics or
ethnic group affiliation.”1 Different types of racial and ethnic discrimination have been
described in the literature. Contrada et al. (2001) identified five types of racial and ethnic
discrimination, which include verbal rejection (ethnic and racial slurs or insults),
disvaluation (negative or low expectations of individuals based on their race or ethnicity),
inequality-exclusion (denial of equal treatment), threat-aggression (threats or acts of
physical harm), and avoidance (shunning, exclusion).2 These forms of discrimination
adversely affect multiple areas of individuals’ lives, including when seeking employment,
housing, education, voting, health care, and in dealings with authorities.3
Racial and ethnic discrimination are often considered to be a type of stressor, and
are commonly examined within the context of stress and coping theories and
frameworks.4-7 As a stressor, discrimination has been theorized to affect an individual’s
physical, psychological, social, functional, and spiritual well-being.4,8 Experiences of
racial and ethnic discrimination have been associated with many negative physical health
outcomes in minority populations, such as hypertension, low birth weight, and systemic
inflammation, as well as negative mental health outcomes, including anxiety, early
initiation of substance abuse, psychosis, and depression.9-12
10

Hispanics are the largest and fastest growing minority population in the U.S.,
currently representing over 18% of the nation’s population.13,14 Nearly 70% of U.S.
Hispanics report experiencing ethnic discrimination at some point during their
lifetime.9,13 Considering the association between ethnic discrimination and negative
health outcomes, this level of experienced ethnic discrimination is alarming, and poses a
risk to the health of those in this population, as well as a burden to the U.S. health system.
To date, numerous instruments have been created to measure discrimination in
racial and ethnic minorities. The majority of these instruments have been developed to
measure the experience of discrimination in African American populations, and include
survey specific to the experiences of this population, rather than for other ethnic and
racial minority groups.15 As racial and ethnic minority groups are not all the same, it is
important to have instruments that are specific to the population in which they are being
used. Additionally, many instruments measure one specific dimension of discrimination,
such as workplace discrimination, or measure racial discrimination as one part of a larger
scale measuring overarching constructs, such as stress, coping, or acculturation.16
Discrimination is a pervasive and prevalent problem, and as such, it is vitally important to
have valid and reliable instruments to be able to measure the construct of ethnic
discrimination in this population. Thus, the purpose of this paper is to provide a
systematic review of instruments measuring ethnic discrimination that have been
psychometrically tested and used in Hispanic populations.

2.2

Methods
To identify relevant publications for review, a systematic search of the literature

was conducted electronically using PubMed, Sociological Abstracts, and PsychInfo
11

databases. Keywords for the search were "discrimination", "racial discrimination",
"ethnic discrimination", "Hispanic", 'Latino", and "measurement.” Additionally,
reference lists for all articles selected for full-text review were examined for relevant
citations.
Inclusion criteria for studies were: 1) studies that included a measurement of
racial or ethnic discrimination; 2) use of the instrument in an adult Latino or Hispanic
population; 3) reporting validity and reliability assessments; 4) written and published in
English; and 5) published within the last 20 years, between 1997 and 2018. Exclusion
criteria were: 1) studies in which discrimination was measured as a component of a larger
scale or as a single question or 2) review articles.

2.3

Results
The initial database search yielded 909 articles. Nine records were removed

because of record duplication. Titles and abstracts of the 900 articles were evaluated for
inclusion, from which 32 articles were selected for full-text review. A total of 868 articles
were excluded based on title and abstract review due to failure to meet inclusion criteria.
After full-text review, 16 articles were excluded on the basis of including adolescent or
child participants, lack of reported validity or reliability statistics for the discrimination
instrument used in the study, or assessing experiences of racial discrimination without an
instrument (e.g. one survey question created by investigators). The final review included
16 articles (Figure 2.1).
The 16 articles included in this review described 6 measures of racial/ethnic
discrimination (Table 2.1). In the majority of the articles (n = 14), authors reported
validity and/or reliability statistics of an instrument used to measure discrimination as one
12

of many aspects of a larger study whereas two articles written for the purposes of
psychometrically validating the measurement of discrimination (Table 2.2). In ten of the
16 articles, investigators measured discrimination in Hispanic-only samples, while six
articles measured discrimination in multi-ethnic samples which included Hispanic adults.
2.3.1

Detroit Area Study Discrimination Questionnaire

The Detroit Area Study Discrimination Questionnaire (DAS-DQ) was developed
for the Detroit Area Study in 1995.17 The DAS-DQ consists of 15 items and is comprised
of 2 scales: The Everyday Discrimination Scale and the Major Experiences of
Discrimination. The DAS-DQ is used to measure self-reported discrimination based on
three categories: frequency of everyday mistreatment, recent experiences of
discrimination, and lifetime history of experienced discrimination.18 Although the DASDQ was originally developed with a sample of mostly African Americans and white
participants, the DAS-DQ, and its subscales, have since been used in Hispanic
populations.19-21
2.3.1.1 The Everyday Discrimination Scale
The Everyday Discrimination Scale is a 9-item scale that measures minor
experiences of unfair treatment that are categorized as occurring chronically and
routinely.17 The nine items of this scale address being treated with less courtesy or
respect than others, receiving poorer service in stores or restaurants than others, people
treating you like you are not as smart as they are, others acting as if they are better than
you, people being afraid of you, people thinking you are dishonest, being called names or
being insulted, and being threatened or harassed. To each question, respondents answer
13

the frequency with which they have experienced each situation. Response options include
never (1), rarely (2), sometimes (3), and often (4). Scores for the Everyday
Discrimination Scale are calculated summing the nine items, with higher scores
representing more frequent experiences of everyday discrimination.17 Of the DAQ-DS
scales, the Everyday Discrimination Scale is the most commonly used, particularly in
Hispanic populations.9,19-23 It has also been used to assess construct validity in new
discrimination instruments, and has been translated from English to Spanish for this
purpose.24 Internal consistency reliability of the Everyday Discrimination Scale has been
well-established. In studies with large Hispanic samples, Cronbach’s alpha values ranged
from 0.86-0.91.9,19-22
Taylor, Kamarck, and Shiffman (2004) were the first to validate the Everyday
Discrimination Scale. This was in an African American sample and in the study,
convergent validity of this scale was established by examining the relationship between
the Everyday Discrimination Scale and Ecological Momentary Assessment.18 Molina,
Alegria, and Mahalingham (2013) later tested the validity of the Everyday Discrimination
Scale in a sample of over 2,000 Hispanic adults using Confirmatory Factor Analysis
(CFA).23 Results of the CFA were consistent with factor analyses conducted in African
American samples by Taylor and colleagues (2004), and revealed a single-factor
solution.23 The comparative fit index indicated a good fit to the data (.91), and the root
mean square error of approximation was .06, which provides evidence for the validity of
the Everyday Discrimination Scale in Hispanic samples.23
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2.3.1.2

Major Experiences of Discrimination

The Major Experiences of Discrimination Scale measures self-reported major
experiences of unfair treatment, such as violations of human rights.18,25 An example item
from this instrument is: “At any time in your life, have you been unfairly fired?” Scores
are based on the number of items that the respondent has indicated experiencing. A
follow up question, at the end of this instrument, asks the respondent to select what they
believe to be the main reason for their experience. Response items to this question
include race, gender, age, and religion, among other potential sources of discrimination.
The Major Experiences of Discrimination originally consisted of 6 items,17 however, a 9item 26 version and a 19-item version 27 have since been developed for use in the Midlife
in the United States (MIDAS) study, and the YES Health Study. The Major Experiences
of Discrimination has been shown to be reliable and valid in a sample of African
Americans, but reliability and validity testing has yet to be conducted in a Hispanic
population.18
2.3.2

Perceived Ethnic Discrimination Questionnaire- Community Version

The Perceived Ethnic Discrimination Questionnaire-Community Version (PEDQCV) is a 70-item questionnaire that measures perceived experiences of ethnic
discrimination, defined by authors as unfair treatment attributed to one’s ethnicity.15 The
PEDQ-CV was created to measure ethnic discrimination in community-based samples of
any racial or ethnic background.15 The PEDQ-CV was developed based on the Perceived
Ethnic Discrimination Questionnaire (PEDQ), which measures perceived ethnic
discrimination in samples of students.2,15 The PEDQ-CV was used in two studies in this
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review, with samples that include Hispanic adults.15,28 Validity and reliability testing of
the PEDQ-CV was originally conducted with a multi-ethnic sample, of which, 27% were
Hispanic.15 In this study, validity and reliability was examined with each sub-group in the
sample, including with Hispanics. The second study in which the PEDQ-CV was used
measure discrimination also used a multi-ethnic and multi-racial sample, of which 48%
were Hispanic.28 However, the reliability statistics reported for the PEDQ-CV in this
study were for the multi-ethnic sample as a whole, and were not reported for the Hispanic
sub-sample.
The PEDQ-CV is comprised of several sub-scales, including: Lifetime Exposure,
Discrimination in the Media, Discrimination against Family Members, Discrimination in
Different Settings, and Past Week Discrimination. For all scales except the Past Week
Discrimination Scale, respondents indicate how often they have had these experiences
over the course of their lifetime on a 5-point Likert scale. This Likert scale ranges from 1
(“never happened”) to 5 (“happened every day”). The last scale, the Past Week
Discrimination Scale, consists of 10 items, which asks about experiences of
discrimination in the previous week. Responses to these items are ranked on a 4-point
Likert scale ranging from 0 (“never in the past week”) to 3 (“3 or more times in the past
week.”).15
Psychometric testing of the PEDQ-CV was conducted with a sample of college
students and community-dwelling adults, of whom 27% were Hispanic. Principal
component factor analysis was conducted on the 34 items of the Lifetime Discrimination
Scale, which resulted in 7 factors with eigenvalues greater than 1. These 7 factors were
then rotated using the Varimax method, where 4 final factors were identified. Three of
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these factors, Stigmatization/Disvaluation, Threat and Aggression, and
Exclusion/Rejection closely aligned with the factors of the original PEDQ instrument.
Three or more items items loaded onto each factor and together the three factors
accounted for 52% of the variance.15 The fourth factor was identified as discrimination at
work.15
To address construct validity of the PEDQ-CV, known-group comparisons were
conducted between African Americans and Hispanics. Prior research findings have
indicated that public attitudes toward African Americans are more negative than towards
Hispanics, and these findings were reflected in the group comparisons between African
American and Hispanic participants in this study.28 Based on PEDQ-CV scores, African
Americans reported significantly more experiences of discrimination than Hispanics,
providing evidence of construct validity of the PEDQ-CV.28 Internal consistency for the
PEDQ-CV was adequate, as evidenced by Cronbach’s alpha values >.75 for all scales and
subscales of the PEDQ-CV, and >.93 for Hispanics specifically on the Lifetime Exposure
scale of the PEDQ-CV. While the PEDQ-CV has been frequently used by investigators, it
has not been commonly used in Hispanic populations. In a study by Beatty Moody and
colleagues (2016), the PEDQ-CV was shown to have acceptable reliability, with
Cronbach’s alpha values of .91 for the Lifetime Exposure scale and >.78 for the
subscales, as well as a Cronbach's alpha of .92 for the Past Week scale. However, these
values were based on results from a multi-ethnic sample, and not a solely Hispanic
sample.28
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2.3.3

Brief Perceived Ethnic Discrimination Questionnaire- Community Version

A brief version of the PEDQ-CV was created based on the full-length version of
the PEDQ-CV.15 The Brief PEDQ-CV consists of 17 items derived from the original 34
items included in the Lifetime Exposure scale of the PEDQ-CV. This brief version was
created to be used when the PEDQ-CV would create too much participant burden or
when time constraints necessitate a shorter instrument.15
The principal component factor analysis that was conducted during the
psychometric testing of the PEDQ-CV guided the creation of the Brief PEDQ-CV.
Sixteen of the 17 items included in the Brief PEDQ-CV were chosen to be included by
selecting the four items which had the highest factor loadings on each of the four
subscales of the full PEDQ-CV instrument (exclusion/rejection,
stigmatization/discrimination, discrimination at work/school, threat/aggression).15
Reported internal consistency was acceptable for the Brief PEDQ-CV. In a
Hispanic sample, the Cronbach’s alpha value for the Lifetime Exposure Scale was .88,
and Cronbach’s alpha values for all subscales were reported to be >.69 in the
psychometric testing conducted by Brondolo and colleagues.15 In 3 other large studies
with samples of U.S. Hispanics with various countries of origin, the PEDQ-CV
maintained acceptable internal consistency with Cronbach’s alpha values >.73 for all
scales and subscales in each study.29-31
Construct validity of the Brief PEDQ-CV was evaluated using convergent,
concurrent, and discriminant validity.15 Convergent validity was tested with a sample of
student participants, while concurrent and discriminant validity were tested with
community samples. Convergent validity was examined by correlating Brief PEDQ-CV
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scores with other measures of racial discrimination. Brief PEDQ-CV scores were highly
correlated with the Latino Perceived Racism Scale (r = .57, p <.001).15 Concurrent and
discriminant validity were tested by comparing Brief PEDQ-CV scores with Primary
Appraisals of Racist Interactions scores. Providing evidence for concurrent validity, Brief
PEDQ-CV scores were correlated with appraisals of threat and harm included in the
Primary Appraisals of Racist Interactions, while Brief PEDQ-CV scores were not
associated with appraisals of challenge or perceptions of benefit, providing support for
discriminant validity.15 In no other studies were validity statistics reported for the PEDQCV.
2.3.4

Experiences of Discrimination

The Experiences of Discrimination (EOD) Scale is a 9-item scale that measures
self-reported experiences of discrimination in 9 specified situations, such as
discrimination experienced in restaurants or when seeking employment.24,32 The EOD
was developed with a multi-ethnic sample, and has since been used primarily with
African American and Hispanic samples. 24,33-36 The EOD was developed in English and
Spanish and can be administered and scored using 2 different methods. One method is to
use the "situation" version of the EOD. For the situation version, individuals report in
which of nine situations they have experienced discrimination. To score, the sum is taken
of the number of situations in which a participant has reported experiencing
discrimination, with higher scores indicating more experiences of discrimination. For the
second method, individuals are asked to report how often they have experienced
discrimination in each of the nine situations. For this frequency version, values are
assigned based on the frequency of occurrences of discrimination the respondent has
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reported for each situation. Responses of “never” are given a value of 0, “once” a value
of 1, “2 to 3 times” a value of 2.5, and “4 or more times” a value of 5.24 To score, these
values are then summed across the 9 items.
Reliability of the EOD was tested using Cronbach’s alpha and test-retest
reliability. In the Hispanic subset of study participants from the original article describing
this instrument, Cronbach’s alpha values for both frequency-scored and situation-scored
versions of the EOD were reported to be >.71.24 These values were similar to the
Cronbach’s alpha values obtained in a study with a sample of pregnant Latina women.36
Test-retest reliability for the EOD was examined and determined to be acceptable, with
all correlations greater than 0.69 for EOD scores.24
Construct validity for the EOD was tested by examining correlations between
EOD and the Major Experiences of Discrimination and Everyday Discrimination Scales
from the Detroit Area Study- Discrimination Questionnaire.17,24 Statistically significant
correlations were found between these three discrimination scales. Structural Equation
Modeling was also used to determine if the discrimination scales were measuring the
concept of “self-reported racial discrimination.” In the resulting model, controlling for
social desirability, the EOD instrument had the highest correlation with the “self-reported
racial discrimination” construct.
2.3.5 General Ethnic Discrimination Scale
The General Ethnic Discrimination Scale (GED) is an 18-item instrument that
measures perceived ethnic discrimination, and was created to measure perceived ethnic
discrimination in any ethnic group.37 The GED is a modified version of the Schedule of
Racist Events, which is an instrument that was developed for use specifically in African
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American populations.38 To create the GED, the stem of the Schedule of Racist Events
items were changed from “because you are Black” to “because of your race/ethnic
group.”37 The language of the scale was also simplified so that it could be used with
respondents who use English as a second language. It has been used in multi-ethnic
studies, with participants of varying race and ethnicity.37,39,40
Each item of the GED assesses racial/ethnic discrimination in a different area of
life, such as at work, when seeking healthcare, and while in public places. Respondents
answer each item three times, considering how many times they have had these
discrimination experiences in the past year, in their lifetime, and their appraisal of the
stressfulness of the experience. These constitute the three subscales of the GED. Scores
are calculated by summing the scores of each of the three subscales.
Cronbach’s alpha values were used to establish the internal consistency reliability
of the GED. For the Hispanic subset of the original study sample, Cronbach’s alpha
values ranged from 0.93-0.94 for all subscales of the GED.37 In another study, with over
200 Hispanic college students, Cronbach’s alpha for the GED Lifetime Discrimination
subscale was 0.91 and 0.92 for the two administrations of the GED.39
Confirmatory Factor Analysis was used to examine if the three subscales of the
GED measured the construct of perceived ethnic discrimination similarly to the three
subscales of the Schedule of Racist Events. This testing was completed in a multi-ethnic
sample, and all subscales were significant at p <.05 for all ethnic groups. Structural
Equation Modeling also provided evidence that the GED models perceived ethnic
discrimination in the same manner as the Schedule of Racist Events.37
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2.4

Discussion
Through this literature review, six instruments that are used to measure ethnic

discrimination in Hispanics were identified. There were several commonalities among the
instruments. All were multi-item scales that relied on self-report to measure ethnic
discrimination. Most scales aimed to measure discrimination across multiple settings (e.g.
at work, in dealings with authorities, at school, etc.), and across different timeframes
(past week, past year, lifetime).15,17,24,37 There is evidence to support the internal
consistency reliability of each instrument included in this review (all Cronbach’s alpha
values were > .69) among Hispanic-only or multi-ethnic samples. Additionally, there is
evidence to support the validity in Hispanic-only and/or multi-ethnic samples in each of
the instruments.
Factor analyses were conducted to assess instrument validity for several of the
instruments in this review. Confirmatory factor analysis was conducted with the
Everyday Discrimination Scale and the GED; principal factor analysis was conducted for
the PEDQ-CV. Factor analyses revealed several factors, including where individuals
experience discrimination and frequency of the discriminatory experiences. For the
Everyday Discrimination scale, results of both exploratory factor analyses conducted
with a large sample of African Americans 18 and confirmatory analyses later conducted
with Hispanics 23 revealed a single factor for measurement of discrimination defined as
experiences of unfair treatment. This contrasts with 3 factors identified through
confirmatory factor analysis for the GED after it was modified for use with Hispanic
populations. Two of the 3 factors identified (Recent Discrimination, Lifetime
Discrimination) are time-dependent whereas the third factor (stress appraisal) considers
an individual’s perception of the discriminatory experience.37 This is in contrast to the
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single factor of the Everyday Discrimination scale, the purpose of which is to measure
experiences of daily, routine, and minor discrimination. Factor analyses of both the
PEDQ-CV and the Brief PEDQ-CV revealed 4 factors, more than any other of the
instruments. These factors were found to identify types of discrimination experienced
rather than amount of discrimination experienced within specific time periods.15
Other validity testing conducted with these instruments included convergent,
divergent, concurrent, and discriminatory validity testing. The authors of the PEDQ-CV
demonstrated construct validity by using known-group comparisons, where the PEDQCV scores among racial/ethnic groups aligned with rates of experienced discrimination
reported in the literature.15 The brief version of the PEDQ-CV had evidence of
convergent, concurrent, and discriminant validity. Brief PEDQ-CV scores were highly
correlated with other measures of racial discrimination, as well as appraisals of threat and
harm.15 Conversely, Brief PEDQ-CV scores were not strongly correlated with appraisals
or perceptions of benefit or appraisals of challenge, which are included in the Appraisals
of Racist Interaction scales.15 Finally, the EOD scale was highly correlated with the
Major Experiences of Discrimination Scale and the Everyday Discrimination Scale,
providing evidence for concurrent validity of this scale.24
Racial/ethnic discrimination is considered to be a type of stress and is examined
as part of stress frameworks.2,15,37 Thus, the instruments used to assess experiences of
racial/ethnic discrimination should be modeled similarly to instruments measuring stress,
and include measurements of stress appraisal, as is included in the GED.37 The GED is
the only instrument that includes a measurement of stress appraisal in addition to
frequency of discriminatory experiences. However, in order to comprehensively measure
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stress, frequency of experiences should also be included in the measurement. Each
instrument in this review included a measurement of frequency of discriminatory
experiences.
These instruments were not initially created for sole use with Hispanic samples,
but each instrument in this review has been used with Hispanic samples. Of note, not all
instruments in this review have had psychometric testing completed in entirely Hispanic
samples, although some studies reported psychometric testing results in multi-ethnic
samples, in which Hispanics were included. For all instruments, internal consistency
reliability was tested using Cronbach’s alpha values. For the instruments that were tested
in multi-ethnic samples, Cronbach’s alpha values were reported for the Hispanic subsamples for most instruments. However, not all instruments had reported validity testing
results for Hispanic-only samples or Hispanic sub-samples. For the EOD scale and the
GED scale, the researchers conducted and reported validity testing results for the full
sample despite the fact that testing was conducted in multi-ethnic samples.24,37 To
confirm the validity of these instruments in Hispanic populations, future validity testing
needs to be conducted with Hispanic-only samples or, for multi-ethnic samples, with
Hispanic-only subsamples.
When using instruments in Hispanic samples, another consideration needs to be
the language in which the instrument is written. In the U.S., approximately 62% of adult
Hispanics are bilingual, speaking both Spanish and English, with 38% of those primarily
using Spanish.41 Considering this, when conducting research in Hispanic populations,
Spanish and English language versions should be available for participants to select from
to increase accuracy of the measurements and to ensure participant comprehension. The
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EOD scale and the Everyday Discrimination Scale are the only instruments in this review
to have a version of the instrument that has been translated and psychometrically tested in
the Spanish language. Of note, the psychometric testing for both instruments were
conducted on data collected using both the Spanish and English versions thus providing
weaker evidence for the validity of the Spanish version than if psychometric testing had
been conducted separately on the English language and Spanish language versions.24
There was also a large range in the lengths of the instruments in this review. The
shortest instrument was the Major Discrimination Scale, which consisted of 6 items. Most
other instruments were similar in length, ranging from 9 to 18 items. The longest
instrument was the PEDQ-CV, consisting of 70 items. The abbreviated version of this
instrument, the Brief PEDQ-CV, comprised of 17 items, allows the use of an instrument
similar to the PEDQ-CV without the burden of 70 items full length PEDQ-CV. The
brevity of the Everyday Discrimination Scale, the Major Discrimination Scale, and the
EOD may make them more appealing instrument choices when considering participant
burden and available time.
In summary, reliability and validity has been demonstrated in all instruments.
However, availability of Spanish and English language versions of the instrument, length,
and the populations in which the instruments have been tested should be considered. The
Everyday Discrimination Scale was found to be the most commonly used instrument;
however, it only captures everyday discrimination, and not lifetime exposures or stress
appraisals. Comparatively, the 9-item EOD scale has been translated and preliminarily
validated in Spanish. Further, it has also shown good reliability in Hispanic populations
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and shows promising construct validity in a multi-ethnic sample with a large proportion
(43%) of Hispanic participants.24

2.5

Conclusion
Racial/ethnic discrimination is of critical concern in the U.S. High levels of

experienced discrimination have been associated with negative physical and mental
health outcomes. To accurately explore the effect of ethnic discrimination on health
outcomes, measures of racial and ethnic discrimination must be reliable and valid.
Additionally, the instruments must be available in the appropriate language for the
population in which it is being used. The EOD, in Spanish and English, shows promising
validity and reliability in Hispanic populations. Further research is needed to analyze the
validity of this measurement in Hispanic-only populations, as well as the validity of the
Spanish version of the EOD. However, the EOD is a succinct instrument and should be
considered for use when measuring ethnic discrimination in Hispanic populations.

26

Table 2.1 Description of 6 Instruments Measuring Ethnic Discrimination in Hispanic
Samples
Instrument
(year)

Num
ber of
Items

Response Options

Scoring and
Range

Everyday
Discrimination
Scale (1997)

9

Scores are
calculated by
summing items.
Scores range from
0 to 45.

You are
treated with
less courtesy
than other
people.

Major
Discrimination
Scale (1997)

6

Almost every day (5)
At least once a week
(4)
A few times a month
(3)
A few times a year (2)
Less than once a year
(1)
Never (0)
At least once in my
lifetime but not in the
past 12 months (2)
At least once in the
past 12 months (1)
Never (0)

Scores are
calculated by
adding all
responses in each
category. Past 12month
experiences are
summed for
"recent
exposures."
Responses from
the past 12
months or
lifetime are
summed for
"lifetime
exposures"

Have you ever
been unfairly
stopped,
searched,
questioned,
physically
threatened, or
abused by the
police?

Perceived
Ethnic
Discrimination
QuestionnaireCommunity
Version (2005)

70

Scale ranging from 1
(never happened) to 5
(happened very often)

Subscale scores
are computed as
mean of item
responses. Total
score may be
computed as the
mean of subscale
scores. Scores
range from 0 to 5.

Have others
threatened to
hurt you
(ex: said they
would hit
you)?
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Sample Item

Table 2.1 continued
Brief
Perceived
Ethnic
Discrimination
QuestionnaireCommunity
Version (2005)

17

Scale ranging from 1
(never happened) to 5
(happened very often)

Scores are
computed as the
mean of item
responses. Scores
range from 0 to 5.

Have others
made you feel
like an
outsider who
doesn’t fit in
because of
your dress,
speech, or
other
characteristics
related to your
ethnicity?

Experiences of
Discrimination
(2005)

9

For situation version,
questions are
answered yes (1) or no
(0). For frequency
version, responses
include once (1), two
or three times (2), four
or more times (3).

Answers are
summed across
items. For
situation version,
scores range from
0 to 9. For the
frequency
version, scores
range from 0 to
45.

Have you ever
experienced
discrimination
been
prevented
from doing
something, or
been hassled
or made to
feel inferior in
getting credit,
bank loans, or
a mortgage
because of
your race
ethnicity, or
color?

General Ethnic
Discrimination
Scale (2006)

18

Items are scored on
Likert-type scales
from 1 (never) to 6
(Almost all the time).
Each question is
answered three times:
past year experiences,
lifetime experiences,
and stress appraisal

Items are summed
within subscales.
Recent
discrimination
scores range from
18-108; Lifetime
scores range form
18-108. Appraisal
scores range from
17-102.

How often
have you been
treated
unfairly by
institutions
because of
your
race/ethnic
group?
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Table 2.2 Psychometric Properties of 5 Instruments Measuring Ethnic Discrimination
in Hispanic Samples
First Author
(year)

Design

Sample

Reliability

Validity

Everyday Discrimination Scale
Perez (2008)

Crosssectional

2,554
Hispanic
adults in the
U.S.
3,899
Hispanic
adults in the
U.S.
4,539 Asian,
Hispanic, and
African
American
adults in the
U.S. 951
Hispanic
participants.
2,554
Hispanic
adults in the
U.S.

Cronbach's
alpha 0.91

Not reported

Perez (2009)

Crosssectional

Cronbach's
alpha 0.87

Not reported

Chou (2012)

Crosssectional

Cronbach's
alpha 0.91 in
Hispanic
participants

Not reported

Molina (2013)

Crosssectional

Not reported

Crosssectional

719 Hispanic
adults in the
U.S.

Cronbach's
alpha 0.86

Confirmatory factor
analysis supported
the original singlefactor solution. The
single factor
solution had a good
fit to the data
(Comparative Fit
Index = .91)
Not reported

Almeida
(2016)
Cobb (2017)

Crosssectional

122
Cronbach's
undocumented alpha 0.93
Hispanic
adults in the
U.S.
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Not reported

Table 2.2 continued
Perceived Ethnic Discrimination Questionnaire- Community Version
Brondolo
Cross301 African
Cronbach’s
Principal factor
(2005)
sectional
American,
alpha >.75 for analysis using the
Hispanic,
all scales and
Lifetime
white, Asian, subscales of
Discrimination
Native
the PEDQ-CV. scale. Four final
American
Cronbach's
factors aligned with
adults. 27% of alpha >.93 for the original PEDQ
the sample
Hispanics on
scale and accounted
identified as
the Lifetime
for 52% of
Hispanic.
Exposure scale variance. Support
of the PEDQfor construct
CV.
validity through
known-group
comparisons.

Beatty-Moody
(2016)

Longitudinal

607 African
American and
Hispanic adult
participants in
the U.S.
Hispanics
made up 48%
of the sample
(n = 289).
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Cronbach's
alpha for the
Lifetime
Discrimination
Scale was .91.
All Lifetime
Discrimination
subscales had
Cronbach's
alpha values
>.78. The Past
Week scale
had a
Cronbach's
alpha value of
0.92. Values
are for the
entire sample,
not only the
Hispanic
participants.

Not reported

Table 2.2 continued
Brief Perceived Ethnic Discrimination Questionnaire- Community Version
Brondolo
Cross340 college
In the Hispanic Evidence to support
(2005)
sectional
students and
sample, the
convergent,
communityLifetime
concurrent, and
dwelling
Exposure
discriminant
adults. 135
Scale had a
validity. Brief
participants in Cronbach's
PEDQ-CV was
the sample
alpha value of highly correlated
were
0.88. All
with Latino
Hispanic.
subscales had
Perceived Racism
Cronbach's
Scale and
alpha values
appraisals of threat
>.69.
and harm. The
Brief PEDQ-CV
was not associated
with perceptions of
benefit or
appraisals of
challenge in the
Primary Appraisals
of Racist
Interactions scales.
ArellanoCross5,291 adult
Cronbach's
Not reported
Morales
sectional
Hispanics in
alpha 0.88 for
(2015)
the U.S.
the entire
scale. All
subscales had a
reported
Cronbach's
alpha of >.74
Ornelas
Cross5,313 adult
Cronbach's
Not reported
(2016)
sectional
Hispanics in
alpha for all
the U.S.
subscales were
>.73
Corona (2017) Cross198 Hispanic Cronbach's
Not reported
sectional
college
alpha 0.90
students in the
U.S.
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Table 2.2 continued
Experiences of Discrimination
Krieger (2005) CrossThe main
Cronbach’s
sectional
study
alpha values
consisted of
for the
616 multifrequency and
ethnic adult
situation
participants,
versions of the
249 of which
EOD were
identified as
>.71 for
Hispanic. In
Hispanic
the validation participants.
study, the
Test-retest
sample
reliability for
consisted of
the EOD was
208
acceptable,
participants;
with
110 were
correlations
Hispanic.
>0.69 for EOD
scores
Walker (2012)

Nguyen
(2012)

Landrine
(2006)

Prospective
515 pregnant
observational Latina women
in the U.S.

Reported
Cronbach's
alpha values
between 0.750.90
Prospective
677 pregnant
Reported
observational urban Black
Cronbach’s
and Hispanic
alpha value
women.
was 0.74.
General Ethnic Discrimination Scale
Cross1569 multiCronbach's
sectional
ethnic adults
alpha ranged
in the U.S.
from 0.93-0.94
Hispanics
for all
made up 11% subscales in
(n =174) of
the Hispanic
this sample.
segment of this
study sample.

32

Construct validity
was assessed using
correlations
between EOD and
the Major
Experiences of
Discrimination and
Everyday
Discrimination
Scales, with
significant
correlations found
between the scales.
Structural Equation
Modeling provided
evidence that the
EOD was
measuring selfreported racial
discrimination well.
Not reported

Not reported.

Confirmatory factor
analysis was used
to analyze if GED
measured
discrimination
similarly to the
Schedule of Racist
Events. All
subscales were
significant at p <.05
for all ethnic
groups.

Table 2.2. continued
Cheng (2015)

Longitudinal

203 Hispanic
college
students in the
U.S.
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Cronbach's
Not reported
alpha ranged
from 0.91-0.92
for the two
administrations
of the GED.

Figure 2.1 PRISMA 2009 Flow Diagram
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INFLAMMATORY GENOTYPE MODERATES THE ASSOCIATION
BETWEEN ANXIETY AND SYSTEMIC INFLAMMATION IN ADULTS AT
RISK FOR CARDIOVASCULAR DISEASE
3.1

Introduction
Cardiovascular disease (CVD) is the leading cause of death globally.1 In 2016,

CVD accounted for over 17.6 million deaths, and by 2030, is expected to contribute to
over 23.6 million deaths annually.1 Preventing CVD remains a major challenge largely
due to the multifactorial nature of CVD risk factors that range from genetic, to
psychological and behavioral, to environmental factors, and interactions among these
factors. While behavioral and environmental factors have been well studied, less is
known about associations among psychological factors and CVD risk. For example,
while anxiety is associated with increased risk for CVD,2 the exact mechanism(s)
underlying this relationship remain unclear.
Among the proposed mechanisms is a link between high anxiety and unhealthy
lifestyle behaviors that, in turn, increase CVD risk.3 In contrast, others have reported that
CVD risk is increased in individuals with high anxiety due to overactivation of both the
sympathetic nervous system and the hypothalamic-pituitary-adrenal axis, which can lead
to increased plasma catecholamine release, resulting in endothelial damage,
atherosclerosis, and coronary artery disease.3 Yet another proposed mechanism suggests
that anxiety may increase CVD risk through inflammatory pathways, however, evidence
supporting this mechanism has been conflicting. While outcomes from some studies have
suggested that anxiety is positively associated with levels of systemic inflammatory
biomarkers including C-reactive protein (CRP) and interleukin-6 (IL-6),4-6 results from
other studies have not supported these findings.7,8 Further investigation into associations
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between anxiety and inflammation is warranted, as a clearer understanding of systemic
effects of anxiety can improve CVD risk reduction strategies.
Inflammation is known to have a strong genetic component.9 Several common
genetic variants, or single nucleotide polymorphisms (SNPs), located within or near
inflammatory response genes, have been shown to be associated with increased levels of
the circulating inflammatory biomarker proteins, particularly when a SNP resides within
a key regulatory region of the gene, such as a promotor region or an untranslated region
(UTR) (e.g. the 5’- and 3’-UTRs). Among these are variants of the CRP gene (rs1205),10
IL-6 gene (rs1800797),11 and IL-6R gene (rs4129267).12 For example, rs1205 is located
within the 3’-UTR region of the CRP gene, and inheritance of the minor T allele at this
location has been associated with decreased levels of serum CRP protein levels.13,14
Similarly, rs1800797 is located within the IL-6 gene promotor at position (-597), and
inheritance of the minor A allele has been associated with increased systemic levels of
IL-6, and decreased systemic levels of CRP when compared to individuals who inherited
the GG genotype.11,15 Finally, rs4129267 is located in the intron of the IL-6R gene, and
inheritance of the T allele has been reported to be associated with increased IL-6 levels.1618

While studies have been conducted to better understand how inflammatory
genotypes interact with CVD risk factors to influence systemic inflammation levels,9,19
few studies have been conducted to examine whether inflammatory gene variants
moderate associations between anxiety and systemic inflammation. Gaining a better
understanding of the relationship between anxiety and systemic inflammation, as well as
genes that may affect this relationship, would enlarge our current knowledge base of
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health outcomes associated with anxiety, and ultimately aid in the identification of the
mechanism(s) by which anxiety can influence CVD risk. The purpose of this study was to
(1) examine the relationship between anxiety and systemic inflammation; and (2)
determine if SNPs associated with inflammation moderate this relationship. We
hypothesized that anxiety would be a predictor of systemic inflammation. Further, we
hypothesized that inflammatory genotypes would moderate this relationship, with those
with an rs1205 CC genotype, an rs1800797 A allele, or an rs4129267 T allele having
higher levels of systemic inflammation in comparison to participants without these
characteristics.

3.2

Methods
3.2.1

Study Design

This was a secondary analysis of data collected at baseline in a primary research
study entitled “Gene Environment Interactions Regulating CVD Inflammation and
Success of Behavioral Therapies.” The data for the primary research study were
leveraged on the HeartHealth in rural Kentucky study that was conducted from 2009 to
2012 to test the efficacy of a 12-week CVD risk reduction intervention among rural
Kentucky adults with two or more CVD risk factors. The HeartHealth study protocol has
been previously published.20 The “Gene Environment Interactions Regulating CVD
Inflammation and Success of Behavioral Therapies” study was conducted to investigate
the impact of the HeartHealth CVD risk reduction intervention on systemic levels of
inflammation and the influence of inflammatory genotypes on the response. Extensive
baseline and post-intervention data were collected including sociodemographic data,
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clinical history, blood pressure, height, weight, lipid profiles, and smoking status. For the
purposes of the leveraged study, serum for measuring systemic levels of inflammatory
biomarkers and saliva for DNA extraction were collected from participants who
completed baseline and post-intervention data collection.
3.2.2

Sample and Setting

Participants in the HeartHealth study were community-dwelling adults in rural
Kentucky. Participants were 18 years of age or older with two or more CVD risk factors,
including: age > 44 years for men and >55 years for women, a positive family history of
CVD, history of hypertension, abnormal lipid levels or diabetes; current smoker or
tobacco user, body mass index >25 kg/m2, a sedentary lifestyle, or a diet high in saturated
fat. Individuals were excluded if they were non-English speaking, had a history of
chronic drug abuse, end-stage renal, liver, or pulmonary disease; were diagnosed with
active cancer, were diagnosed with gastrointestinal disease requiring special diets, had
cognitive impairment, had physical activity limitations, or were taking protease inhibitors
or other medications that interfere with lipid metabolism. Approval from the University
of Kentucky Institutional Review Board was obtained prior to all study activities, and all
participants provided written informed consent prior to commencement of study
protocols.
3.2.3

Measures
3.2.3.1 Anxiety

Anxiety was measured using the Brief Symptom Inventory (BSI) Anxiety
subscale.21 The scale consists of six items that are used to quantitate the degree of anxiety
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experienced by an individual. Each item is rated on a scale from 0 (not at all) to 4
(extremely) based on the distress caused by the symptom21; the items were summed and
then the average was obtained, with higher total scores indicative of greater anxiety.22
The instrument has demonstrated excellent reliability and validity in non-cardiac and
cardiac samples.21,23 The Cronbach’s alpha value for the current study was .77.
3.2.3.2 Systemic inflammation
CRP and IL-6 are key inflammatory biomarkers.24,25 C-reactive protein and IL-6
are two of the most commonly measured biomarkers to determine levels of systemic
inflammation.24,25 High sensitivity CRP (hsCRP) was measured using a Cholestech
LDX® analyzer (Cholestech LDX Diagnostics, Hayward, CA), a point-of-care
methodology. The Cholestech LDX® system uses reflectance photometry and has wellestablished accuracy and reproducibility for the detection of serum hsCRP.26
To measure serum IL-6 protein levels, 10 ml of whole blood was collected using
anti-coagulant free red top vacutainers. Samples were maintained at room temperature for
at least 30 minutes and no longer than 60 minutes to allow for clotting. Samples were
then centrifuged at 1100 rpm for 15 minutes, after which serum was removed, aliquoted,
and stored in cryovials at −80°C until analyzed. Serum IL-6 was analyzed using a 6-plex
Millipore kit (EMD Millipore, Billerica, MA), and results were read using a Luminex
IS100 (Luminex, Austin, TX), following manufacturers’ protocols.
3.2.3.3 SNP genotyping
Whole expectorated saliva was collected from participants using Oragene® DNA
Collection Kits. From these samples, genomic DNA was isolated according to the
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manufacturer’s instructions.27 Purified DNA was suspended in 10mM Tris-HCl, 1 mM
EDTA pH 8.0 (Thermo Fisher, Wilmington, DE), and DNA concentrations were
measured using the NanoDrop-1000 spectrophotometer (Fisher Scientific, Fair Lawn,
NJ). SNP genotyping of purified genomic DNA was performed utilizing Taqman®
Genotyping Assay Kits and reagents (Applied Biosystems/Thermo Fisher Scientific.
Carlsbad, CA) in the Roche LightCycler 480® Instrument (Roche Applied Science.
Indianapolis, IN). For the purposes of this study, we examined a single SNP in each of
the CRP (rs1205), IL-6 (rs1800797), and IL6R (rs4129267) genes. All SNPs tests
maintained Hardy-Weinberg equilibrium (p > 0.05). Genotypes were coded as follows:
(1) for rs1205, participants homozygous for major C alleles were compared to those who
were CT heterozygous and TT homozygous; (2) for rs1800797, participants who were
major G allele homozygotes were compared to GA heterozygotes and minor allele A
homozygotes; and (3) for rs4129267, participants homozygous for the major C allele
were compared to those who were CT heterozygotes or were homozygous for the minor
T alleles.
3.2.3.4 Body Mass Index
Height and weight were measured with a professional grade stadiometer and a
professional grade digital body weight scale at baseline for all participants. Body mass
index (BMI) was calculated using the formula body weight (kilograms) divided by height
(meters) squared. Body mass index was entered into analyses as a continuous variable.
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3.2.3.5 Smoking status
Smoking status was determined from self-report. Participants were asked to
identify if they were a never smoker, quit smoking 1 or more years ago, quit smoking less
than one year ago, or were a current smoker. Responses were collapsed into 2 categories:
participants who had never smoked or had quit 1 or more years prior were categorized as
non-smokers; participants who had quit less than 1 year ago or were current smokers
were categorized as current smokers.
3.2.3.6 Demographic characteristics
Demographic information was collected via self-report questionnaire. Data
included age in years, race/ethnicity, and gender. For race/ethnicity, participants were
asked to self-identify as being non-Hispanic white or Caucasian, non-Hispanic black or
African American, Asian, Hispanic or Latino, American Indian or Alaskan Native,
Native Hawaiian or other Pacific Islander, or other. Reflective of the rural Kentucky
population, 89% of participants in the HeartHealth study self-identified as being nonHispanic white or Caucasian. To control for population stratification, analyses in this
study were limited to participants who self-identified as being non-Hispanic white.
3.2.4

Data Analysis

Descriptive analyses included frequency distributions or means and standard
deviations, as appropriate for each variable of interest. Chi square analyses and
independent t-tests were used to assess sociodemographic differences between genotypes.
Multiple linear regression modeling was conducted to examine whether anxiety
was associated with serum CRP and IL-6, adjusting for age, gender, BMI, and smoking
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status. To test moderation effects, hierarchical multiple linear regression modeling was
conducted to examine if rs1205, rs1800797, or rs4129267 genotypes moderated
associations between anxiety and serum hsCRP or IL-6. In each of the models, block one
included age, gender, BMI, smoking status, and anxiety score, and genotype for either
rs1205, rs1800797, or rs4129267, and the outcome variable of either serum hsCRP levels
or serum IL-6 protein levels. An interaction term for anxiety and each genotype (anxiety
* genotype) was entered in the second block of the regression model to test whether the
relationship between anxiety and systemic inflammation varied according to genotype.
For each significant interaction term, a subsequent simple slope analysis was conducted
to determine the nature of the moderation effect.
To limit the overall Type I error rate, serum CRP and IL-6 protein levels were
selected as the only outcome variables (i.e., indicators of the systemic inflammatory
status) based on the reviewed literature.2,4-6 For each outcome variable (CRP and IL-6
protein levels), three models were considered (one for each genotype). Given the
purposeful limit imposed on number of cytokines and number of genotypes, we
maintained an a priori alpha level of .05 throughout. Consistent with prior analyses and
as a correction for skewed distributions, both hsCRP and IL-6 variables were log-10
transformed prior to analysis.
All data analyses were performed using SPSS Statistics for Windows version 26
(IBM Corp., Armonk, N.Y., USA) except for simple slope analysis, for which ModGraph
Internet Version, version 3.0 (Victoria University of Wellington, Wellington, New
Zealand) was used.28,29
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3.3

Results
3.3.1

Sample Characteristics

Characteristics of the sample (N = 398) are summarized in Table 1. The majority
of participants were female (73.4%) with a mean age of 51.4 ± 13.3 years. Most of the
sample were non-smokers (88.7%). The mean BMI for this sample was 32.8 ± 7.4 kg/m2.
There were no significant differences in sociodemographic characteristics found when
comparing genotypes for all three SNPs examined (data not shown).
3.3.2

Associations between anxiety and levels of inflammatory biomarkers

Table 2 shows results of the regression analysis conducted to examine if anxiety
predicted serum hsCRP protein levels controlling for age, gender, BMI, and smoking
status. While the overall model was significant (F(5, 392) = 24.45, p < 0.001), this was
due to the significant associations of gender, smoking status, and BMI with serum hsCRP
protein levels; anxiety was not a significant predictor of hsCRP protein levels.
Additionally, the regression model examining whether anxiety predicted serum IL-6
protein levels was not significant (Table 3).
3.3.3

Moderating effects of inflammatory genotypes on associations between anxiety
and levels of inflammatory biomarkers
Three models were analyzed to examine if the rs1205, rs1800797, or rs4129267

SNPs moderated the association between anxiety and serum IL-6 protein level. Of the
three models, the two hierarchical linear regression models examining whether the rs1205
or rs1800797 SNPs moderated the association between anxiety and serum IL-6 protein
level were not found to be significant (F(7, 390) = 1.607, p = .132 and F(7, 390) = 1.56, p

43

= 0.146, respectively). The third model which examined the moderation effect of the IL6R gene SNP, rs4129267, was found to be significant (R2 = 0.042, F(7, 390) = 2.42, p =
0.019). In this final model, the interaction term between anxiety and rs4129267 genotype
was significant (β = -0.235, p = 0.010), indicating a significant moderation effect. The
subsequent simple slope analysis revealed that anxiety was only significantly associated
with IL-6 protein levels for those with an rs4129267 CC genotype (b = 0.243, SE = 0.04,
p <0.001) and not for those with a CT or TT genotype (p = 0.770) (Figure 1).
Three additional models examined whether rs1205, rs1800797, or rs4129267
SNPs moderated the association between anxiety and serum CRP level. In these models,
there was no evidence that rs1205, rs1800797, or rs4129267 genotypes moderated the
association between anxiety and serum CRP level.

3.4

Discussion
In previous studies, anxiety has been reported to be associated with increased

levels of systemic inflammation.2-4,30,31 However, this relationship has not been
consistently supported in the literature,7,8 and was not supported in this study (Tables 2
and 3). In accord with the results of our study, anxiety was not significantly associated
with either serum hsCRP or IL-6 levels. The lack of consistency in the association
between anxiety and systemic levels of inflammation suggests that other variables may
influence this relationship.
Genetic variants previously associated with increased systemic levels of
inflammatory biomarkers were examined as potential moderators of the association
between anxiety and inflammation.13,19,32 Of the three SNPs (rs1205, rs1800797, and
rs4129267) examined in this study, the rs4129267 SNP, located on the IL-6R gene, was
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found to have a moderating effect on the association between anxiety symptoms and
serum IL-6 levels. Results of the simple slope analysis indicated that the association
between anxiety and inflammation was only significant for individuals with the
rs4129267 CC genotype. The IL-6R SNP, rs4129267, examined in this study has been
reported to be in complete linkage disequilibrium with a second IL-6R SNP, rs2228145,
with the minor C allele of rs2228145 co-inherited with the minor T allele of rs4129267.16
The rs2228145 SNP is responsible for an amino acid change, Asp(358)Ala, that results in
a modification to the structure of the IL-6 receptor.16 This amino acid change increases
the cleavage of the IL-6 receptor from the cell surface into the extracellular space, where
the IL-6 receptor can then associate with free IL-6.17,18,33 The resulting complex is then
recognized by glycoprotein (gp) 130 structures on the membrane of most cells in the
body, providing an alternate IL-6 signaling pathway, known as IL-6 trans-signaling.17,18,33
As compared to classic IL-6 signaling, where IL-6 associates with membrane-bound IL-6
receptors that are expressed by only a few types of cells in the body, IL-6 trans-signaling
can occur in many types of cells throughout the body, and is reported to be a proinflammatory process, and may explain findings from this study.17
The pro-inflammatory nature of the T allele of rs4129267 is reflected in our
findings. There was no significant association between anxiety and IL-6 levels for those
with the rs4129267 CT or TT genotype, but rather, as demonstrated in the simple slope
analysis results, those with the CT or TT genotype had higher IL-6 levels, with no regard
to level of anxiety. This suggests that individuals with CT or TT rs4129267 genotypes
may experience persistent elevated systemic inflammation regardless of anxiety levels.
Conversely, our findings suggest that those with an rs4129267 CC genotype, which has
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not been reported to be associated with increased systemic inflammation, may experience
an increased inflammatory response to stressors, such as anxiety.
Other SNPs examined did not have a moderating effect on associations between
anxiety and levels of serum hsCRP or IL-6. Among these was rs1205. Located within the
CRP gene, the minor T allele of rs1205 has been associated with lower circulating levels
of CRP.13,14,34 In the two models which examined rs1205 genotype, genotype was not a
significant predictor of CRP or IL-6 levels, nor was there evidence that genotype
moderated the relationship between anxiety and systemic inflammation. The second SNP
examined in this study was rs1800797, located on the IL-6 gene. The minor A allele of
the rs1800797 SNP has been associated with increased IL-6 levels and decreased CRP
levels when compared to GG genotypes.11,15 Like rs1205, rs1800797 was not found to be
associated with IL-6 or CRP levels, nor did it have a moderating effect on the relationship
between anxiety and inflammation.
Of note, in the two models examining the moderation of rs1205 and rs1800797 on
the association between anxiety and CRP, gender, BMI, and smoking status were found
to be significant predictors of CRP. These are expected findings, as female gender,
increased BMI, and smoking are well-established predictors of systemic inflammation,
and are commonly adjusted for in analyses examining novel associations with systemic
inflammation.35
This study adds to the current literature that reports an association between
anxiety and systemic inflammation by suggesting that certain inflammatory genotypes
may be more susceptible to the negative effects of anxiety, resulting in increased
inflammation. Few studies have been conducted to examine associations between anxiety

46

and inflammation, and fewer still to test moderating effects of inflammatory genotypes
on these associations. The findings from our study add to the knowledge of how specific
genotypes might place some individuals at risk for increased systemic inflammation that
can, in turn, increase risk for CVD. Additional research is needed to examine these
relationships further, and to replicate and validate the findings of this preliminary study.
3.4.1

Strengths and Limitations

To control for population stratification, the analyses were limited to participants
who self-identified as non-Hispanic white or Caucasian. It will be of interest in future
studies to examine these relationships in more diverse samples. Second, while we had a
large sample representative of rural populations at high risk for CVD, additional studies
with larger samples will be critical both to verify our preliminary findings, and to support
conducting a larger number of analyses with correction for multiple comparisons.

3.5

Conclusion
Anxiety is associated with increased risk for CVD. The mechanism that underlies

this relationship is not known, although inflammatory pathways have been hypothesized
to be a potential mechanism. In this study, anxiety was positively associated with serum
IL-6 protein levels, but a moderation analysis indicated that this association was
significant only for individuals with the rs4129267 CC genotype. These findings suggest
that there may be genotypic differences in individuals’ responses to anxiety, which may
place certain individuals at higher risk than others for inflammation, and subsequently
CVD. Further studies are needed to provide more robust evidence of these relationships,
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from which interventions can be tailored based on genotypic differences to improve CVD
prevention efforts.

Table 3.1 Participant Characteristics

Total Sample (N=398)
Age (years)

51.4 ± 13.3

Gender (male)

106 (26.6%)

Never or former smoker

353 (88.6%)

Body mass index (kg/m2)

32.8 ± 7.4

Anxiety score

0.5 ± 0.5

hsCRPa (mg/L)

3.3 ± 3.7

IL-6b (pg/L)

16.4 ± 34.3

Values reported as either mean ± SD or n (%).
a

high sensitivity C-reactive protein

b

Interleukin-6
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Table 3.2 Summary of Multiple Linear Regression Predicting Serum High Sensitivity
C-reactive Protein Level (N= 398)
B

𝝱

95% CI for B

p value

Age

0.002

0.057

(-0.001, 0.006)

0.209

Gender (male)

0.218

0.191

(0.116, 0.319)

<0.001

Body mass index

0.029

0.425

(0.023, 0.035)

<0.001

Smoking status
(never or former)

0.163

0.102

(0.022, 0.304)

0.023

Anxiety score

0.064

0.069

(-0.019, 0.148)

0.128

Variable

Overall: R2 = 0.238, p <0.001
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Table 3.3 Summary of Multiple Linear Regression Predicting Serum Interleukin-6
Protein Level (N = 398)
B

𝝱

95% CI for B

p value

Age

0.001

0.016

(-0.003, 0.005)

0.753

Gender (male)

-0.072

-0.061

(-0.190, 0.046)

0.232

BMI

0.004

0.062

(-0.003, 0.011)

0.216

Smoking status (never or
former)

-0.133

-0.081

(-0.297, 0.031)

0.111

Anxiety score

0.100

0.103

(0.003, 0.197)

0.043

Variable

Overall: R2 = 0.022, p = 0.116
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Table 3.4 Summary of hierarchical multiple linear regression to examine moderating
effects of rs4129267 genotype on associations between anxiety and serum IL-6 protein
level

Variable

B

𝝱

95% CI for B

p
value

Step 1

Age

0.001

0.015

(-0.003, 0.004)

0.772

Gender (male)

-0.073

-0.062

(-0.191, 0.045)

0.227

BMI

0.004

0.062

(-0.003, 0.011)

0.222

Smoking
status (never,
former)

-0.133

-0.081

(-0.296, 0.031)

0.112

Anxiety score

0.100

0.103

(0.003, 0.196)

0.044

rs4129267
(CC)

0.057

0.054

(-0.047, 0.160)

0.281

Step 2

Age

0.000

0.008

(-0.004, 0.004)

0.867

Gender (male)

-0.075

-0.064

(-0.192, 0.042)

0.207

BMI

0.005

0.065

(-0.002, 0.011)

0.197

51

R

R2

R2
change

0.159

0.025

0.003

0.204

0.042

0.017

Table 3.4 continued
Smoking
status (never
or former)

-0.143

-0.087

(-0.306, 0.020)

0.085

Anxiety score

0.243

0.251

(0.098, 0.388)

0.001

rs4129267
(CC)

0.191

0.182

(0.047, 0.336)

0.010

Anxiety *
rs4129267
genotype

-0.252

-0.235

(-0.443, -0.061)

0.010
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Figure 3.1 Association between anxiety and IL-6 by rs4129267 genotype

CC genotype: b = 0.24, SE = 0.04, p <0.001
CT + TT genotype: p = 0.770
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EXPERIENCES OF ETHNIC DISCRIMINATION AND VAL158MET
POLYMORPHISM ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN
HISPANIC ADULTS AT RISK FOR CARDIOVASCULAR DISEASE
4.1

Introduction
Hispanics are the largest and fastest growing minority population in the U.S.,

currently representing 18.3% of the nation’s population.1 Nearly 70% of U.S. Hispanic
adults report experiencing ethnic discrimination during their lifetime.2 Discrimination, as
defined by Clark and colleagues, consists of the “beliefs, attitudes, institutional
arrangements, and acts that denigrate individuals or groups because of phenotypic
characteristics or ethnic group affiliation.”3 Racial and ethnic discrimination adversely
affects multiple areas of individuals’ lives, including employment, housing, education,
voting, health care, and in interactions with authorities.4
Discrimination is a chronic stressor that is associated with negative physical and
mental health outcomes in racial and ethnic minority populations.5-7 This includes a
higher propensity for the development of cardiovascular disease (CVD). In a multi-ethnic
sample from a national longitudinal study, Everson-Rose and colleagues (2015) reported
that a one standard deviation increase in experiences of lifetime discrimination was
associated with an 11% increase in CVD risk. Further, experiences of racial/ethnic
discrimination have also been associated with known CVD risk factors, including
elevated levels of systematic inflammation, elevated blood pressure, and feelings of
anxiety.2,8-10 Although associations between discrimination and depression in Hispanic
adults have not been well-studied, strong associations between experiences of
discrimination and depressive symptoms have been demonstrated in research with
African American populations.11-13
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The underlying pathway of this relationship is not well understood. Chronic stressors,
such as experiences of discrimination, have been proposed to result in dopaminergic
pathway dysregulation in the brain, beginning with increased levels of dopamine in
response to the stressor.14,15 In response to this overstimulation of the dopaminergic
system, an adaptive downregulation of the dopaminergic system may occur, which
includes decreased transmission of dopamine throughout the brain.16,17 Subsequently, the
decreased transmission of dopamine is associated with common depressive symptoms
including anhedonia, decreased motivation, sleep disruption, and decreased energy.18,19
Given the role of dopamine in depressive symptoms, genetic variants associated with
dopamine activity may affect the relationship between chronic stress, such as
discrimination, and depressive symptoms. One such variant is the Val158Met
polymorphism in the catechol-o-methyltransferase (COMT) gene, located on
chromosome 22. This gene encodes the COMT enzyme that is responsible for dopamine
degradation in the prefrontal cortex.20 COMT with the common valine (Val) allele is
more stable than COMT with the less abundant methionine (Met) allele.21 COMT
enzymatic activity in Val-Val homozygous individuals may be increased by as much as
50%, relative to Met-Met individuals, while COMT activity in heterozygous individuals
may be increased by as much as 12% relative to Met-Met individuals.22 Combined with
elevated levels of dopamine resulting from prolonged stress, such as experiences of
discrimination, the decreased dopamine degradation seen with the Met allele may
increase the body’s compensatory response and ultimately decrease the body’s
responsiveness to dopamine. This could result in higher risk for depressive symptoms in
those heterozygous or homozygous for the Met allele.23

55

Better understanding of the relationship between ethnic discrimination and
depressive symptoms, and identification of genes that influence this relationship, could
support early identification of people at greatest risk for depressive symptoms who are
appropriate for early intervention. The purpose of this study was to examine the
relationship between lifetime experiences of ethnic discrimination and depressive
symptoms; between Val158Met polymorphism and depressive symptoms; and to explore
the moderating effect of Val158Met polymorphism on the association between
discrimination and depressive symptoms in Hispanic adults.

4.2

Methods
4.2.1

Study Design

This was an analysis of data from a genetic sub-study that was leveraged on the
“Corazón de la Familia (Heart of the Family)” study. The Corazón de la Familia study is
a randomized controlled trial conducted to examine the effects of a family dyad
intervention to reduce CVD and type 2 diabetes (T2D) risk in Hispanics with two or more
risk factors. Extensive baseline data were collected as part of the Corazón de la Familia
study, including sociodemographic data, clinical history, and depressive symptoms from
both members of the participating family dyad. The sub-study was conducted to
investigate the effects of experiences of ethnic discrimination and genetic variations on
symptoms of depression in Hispanic adults at risk for CVD. For the purposes of the
leveraged study, saliva for genomic DNA extraction and subsequent genotyping was
collected from participants who completed baseline data collection.
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Prior to commencement of the study, all study protocols and materials were
approved by the University of Kentucky Institutional Review Board. Prior to
participation in any study procedures, written informed consent was provided by all
participants. Following informed consent, data collection questionnaires were completed
by each member of the participating dyad separately. Saliva samples were collected from
participants after completion of the data collection questionnaires.
4.2.2

Sample and Setting

Participants were community-dwelling Hispanic adults who resided in central
Kentucky. Family dyads were recruited including (1) a primary participant who had two
or more risk factors for CVD or T2D, but did not have a diagnosis of either condition,
and (2) a co-participating family member with or at risk for CVD or T2D. Other inclusion
criteria were that participants were primary Spanish speakers 18 years of age and older.
Individuals were excluded from this study if they had cognitive impairment that
precluded either member of the dyad from understanding the consent process or
participating in the intervention as evaluated using the Spanish-language version of the
Mini-Cog; had a major psychiatric (e.g., schizophrenia) condition; or had medical
contraindications to participating in a lifestyle intervention. Either member of the parent
study’s family dyad was eligible to participate in the genetic sub-study, and the sample in
this study consists of both principal members of the dyad, as well as family dyad
members.
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4.2.3
4.2.3.1

Measures

Sociodemographic and clinical characteristics

Data were collected via self-report at baseline of the parent study. These data
included participant age and sex. Socioeconomic status was assessed using a measure of
financial comfort in which participants were self-categorized into 2 groups: having
enough or more than enough money to make ends meet or having not enough money to
make ends meet. Educational level was collected, and participants were categorized as
having a high school education or less or as having more than a high school education.
Marital status data were collected, and participants were categorized as being single,
divorced, or widowed as compared to married or cohabitating. Additionally, clinical
information was collected which included a list of currently prescribed medications.
4.2.3.2

Acculturation

Marin’s Acculturation Scale was used to measure acculturation. This 12-item
scale measures acculturation to U.S. culture among Hispanic individuals. The 12 items of
this instrument address three domains of acculturation: “language use”, “media”, and
“ethnic social relations”.24 Participants respond to each item on a 5-point Likert scale that
ranges from 1 (only Spanish) to 5 (only English). The score is calculated by summing
across the 12 items, with higher scores indicative of more acculturation to the U.S.
culture. In this sample, the reliability of this instrument was found to be acceptable, with
a Cronbach’s alpha of 0.80.
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4.2.3.3 Experiences of discrimination
Ethnic discrimination is the unfair treatment of individuals or groups based on
phenotypic characteristics or ethnic group affiliation.3 Experiences of ethnic
discrimination were assessed using the Experiences of Discrimination (EOD) instrument.
This is a 9-item instrument that asks the respondent to identify situations in which they
have ever experienced discrimination as a result of their ethnicity, such as at school or
work or in accessing medical care or seeking housing. For any situation in which
discrimination has been experienced, the participant identified how often; response
options consisted of “Never” (score = 0), “once” (= 1), “2-3 times” (= 2.5), and “4 or
more times” (= 5). The score is summed across the 9 items and ranges from 0 to 45;
higher scores indicate more frequent experiences of discrimination. Reliability and
validity for English and Spanish versions of the EOD have been demonstrated in
Hispanic populations, with Cronbach’s alpha values ranging from 0.71 to 0.90 for both
English and Spanish language versions.25-27 In this sample, the Cronbach’s alpha for the
Spanish language version of the EOD instrument was 0.77.
4.2.3.4 Val158Met Polymorphism
Two milliliters of whole expectorated saliva were collected from participants
using Oragene® DNA OG-500 Collection Kits. Genomic DNA was isolated from these
samples according to the manufacturer’s instructions.28 Purified DNA was suspended in
100 μL of elution buffer (New England Biolabs, Inc, Ipswich, MA), and purified DNA
was quantified by UV absorbance with a NanoDrop 2000/2000c Spectrophotometer
(Thermo Scientific, Waltham, Massachusetts). Samples were then genotyped for the
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Val158Met SNP in the COMT gene. Genotyping of purified genomic DNA was
performed utilizing Taqman® Genotyping Assay Kits and reagents, according to the
manufacturer’s protocol (Applied Biosystems/Thermo Fisher Scientific. Waltham,
Massachusetts). Genotypes were determined using a CFX Real Time PCR system
(BioRad). The Val158Met SNP maintained Hardy-Weinberg equilibrium (p > 0.05). For
the purposes of the analysis, participants were categorized as having a Val/Val genotype
or Val/Met + Met/Met genotype.
4.2.3.5 Depressive symptoms
The Patient Health Questionnaire-8 (PHQ-8) consists of 8 items used to assess
depressive symptom frequency over the previous two weeks.29 The 8 items are based on
Diagnostic and Statistical Manual of Mental Disorders (DSM) IV diagnostic criteria for
depressive disorders.29 Scores range from 0 to 27, with each item scored as 0 (not at all),
1 (several days), 2 (more than half the days), and 3 (nearly every day). Higher PHQ-8
scores indicate higher levels of depressive symptoms. Spanish and English versions have
been shown to have high specificity and sensitivity when compared to structured
psychiatric interviews conducted by mental health professionals,29,30 as well as
appropriate validity and reliability.30,31 In this sample, internal reliability was acceptable,
with a Cronbach’s alpha value of 0.83.
4.2.4

Data Analysis

Descriptive analyses to characterize the sample included frequency distributions
or means and standard deviations, as appropriate for each variable of interest.

60

Hierarchical multiple linear regression modeling was conducted to examine (1)
the relationship between discrimination experiences and depressive symptoms (block 1 of
the hierarchical regression model); (2) the relationship between Val158Met
polymorphism and depressive symptoms (block 2 of the model); and (3) whether the
Val158Met polymorphism moderated the association between experiences of
discrimination and depressive symptoms (block 3 of the model). The model was adjusted
for age, gender, acculturation, marital status, educational level, and financial status.
Experiences of discrimination was included in block 1 of the model, in addition to the
control variables listed. The Val158Met polymorphism was entered into the second block
of the regression model. An interaction term for discrimination and Val158Met
(discrimination * Val158Met) was entered in the third block of the regression model.
All statistical analyses were performed using SPSS version 26 (IBM, Armonk,
NY), and an a priori alpha level of 0.05 was used to determine significance in all
analyses.32 All variables were examined to ensure they met the statistical assumptions for
the analyses performed.

4.3

Results
4.3.1

Sample Characteristics

Characteristics of the sample are summarized in Table 1. The majority of
participants were female (74.2%) with a mean age of 40.2 ± 9.3 years. The mean
acculturation score for this sample was 20.9 ± 5.2, showing that the sample was less
acculturated to the U.S. culture. In this sample, 79% reported their household income to
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be enough or more than enough to make ends meet. Participants reported low levels of
experienced ethnic discrimination (2.9 ± 5.1) and depressive symptoms (2.7 ± 3.3).
4.3.2 Associations between experiences of discrimination, Val158Met polymorphism,
and depressive symptoms
Results of the hierarchical multiple linear regression are presented in Table 2.
Block 1 examined the association between experiences of discrimination and depressive
symptoms (F(7, 116) = 2.151, p = 0.044). Findings from this block showed experiences
of discrimination to be a significant predictor of depressive symptoms (p = 0.034), with
more experiences of discrimination associated with higher depressive symptoms. In block
2, the Val158Met polymorphism was assessed as a predictor of depressive symptoms
(F(8,115) = 2.471, p = 0.016). Regarding the Val158Met polymorphism, carriers of the
Met allele had higher levels of depressive symptoms compared to those homozygous for
the Val allele. Block three of the regression examined if the Val158Met polymorphism
moderated the association between experiences of discrimination and depressive
symptoms. The final block of the model was significant (F(9, 114) = 2.200, p = 0.027),
and revealed significant main effects of age (p = 0.017), experiences of discrimination (p
= 0.041), and the Val158Met polymorphism (p = 0.049) on depressive symptoms.
However, the interaction term between experiences of discrimination and the Val158Met
polymorphism was not significant (p = 0.682), indicating that the Val158Met
polymorphism does not moderate the relationship between experiences of discrimination
and depressive symptoms. In all three blocks of the regression model, of the control
variables, only age was associated with depressive symptoms, with depressive symptoms
decreasing with age.
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4.4

Discussion
The demonstration of a significant association between experiences of ethnic

discrimination and depressive symptoms in this study adds to a growing body of research
in which similar outcomes have been reported in studies conducted with other
populations.12,33,34 For example, in a study conducted to investigate the association
between experiences of racial discrimination and depressive symptoms in older African
American adults, Nadimpalli and colleagues (2015) found for every increase in a measure
of discriminatory experiences, participants were 1.2 times more likely to report higher
levels of depressive symptoms.11 Similar findings have been reported in studies
conducted with multi-ethnic samples.35 The few studies conducted with Hispanics of
Mexican origin,36 Hispanic adolescents37,38 and emerging Hispanic adults39 have also
shown a positive relationship between experiences of discrimination and depressive
symptoms. Although few studies have been conducted to investigate the association
between experiences of discrimination and depressive symptoms in a heterogeneous
sample of U.S. Hispanic adults, as this study was, Torres and Ong (2010) examined these
associations in a sample of 91 Hispanic adults that, similar to our sample, were from
various countries of origin.40 Similar to the findings from this study, Torres and Ong also
found that greater experiences of discrimination were positively associated with
depressive symptoms.40 Findings from this study add to a limited, but growing, body of
research showing these associations in Hispanic adults in the U.S.
Findings from other studies have indicated there are associations between the
Val158Met polymorphism and depressive symptoms, with the Met allele associated with
higher levels of depressive symptoms.41-44 For example, in a sample of 405 people, Aberg
and colleagues found that depressed participants were nearly 1.5 times more likely to
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have a Val/Met or Met/Met genotype.41 Similarly, we found the Val158Met
polymorphism was found to be an independent predictor of depressive symptoms in our
sample, with the Met allele associated with increased depressive symptoms.
The Val158Met polymorphism is located in the gene that encodes catechol-Omethyltransferase, or COMT, an enzyme that catabolizes catecholamines, such as
dopamine, to physiologically inactive metabolic products.20,44 The Val158Met
polymorphism has been associated with a three to four fold variation in COMT activity,
with those homozygous for the Val allele having higher COMT enzymatic activity than
those homozygous for the Met allele.21,22 Our findings show increased depressive
symptoms in participants with at least one Met allele. This coincides with the outcomes
of several well-designed studies, where the Met allele was also reported to be positively
associated with depressive symptoms.41-43 The increased risk for depressive symptoms
seen with the Met allele may be due to lower COMT enzyme activity associated with the
Met allele.21,22 The slower COMT enzyme activity results in consistently higher levels of
dopamine. The overstimulation caused by the high levels of dopamine may, in turn,
decrease the body’s responsiveness to dopamine.16 This decreased responsiveness to
dopamine could result in the presence of depressive symptoms.45
Conversely, there have been studies which report the Val allele of the Val158Met
polymorphism to be associated with increased depressive symptoms.46-48 Of note, the
sample populations in these studies are primarily of European/Caucasian or Asian
descent. Further, a recent meta-analysis reported differences in the Val158Met allele
associated with depression risk in two different ethnic populations.48 In the East Asian
sample in the meta-analysis, the Met allele was found to be the allele associated with
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depression, while in the European sample, the Val was the allele associated with
depression.48 To our knowledge, the association between the Val158Met polymorphism
and depressive symptoms has not been investigated in Hispanic individuals, and may
explain differences in our findings than in those who report the Val allele to be associated
with increased depressive symptoms.
While investigators have examined biological mechanisms that could potentially
underlie the association between ethnic discrimination and health outcomes, this
association is still not well understood.5,7,49,50 Due to the stressful nature of ethnic
discrimination, and effect of stress on dopamine levels in the brain,51 the Val158Met
polymorphism was investigated as a potential moderator of this relationship. It was
hypothesized that the Val158Met polymorphism would moderate the relationship
between experiences of discrimination and depressive symptoms, given the genotype’s
association with dopamine activity,20 and the role of dopamine in depression.19 However,
findings from this study indicated no moderation effect of Val158Met polymorphism on
this relationship, suggesting that experiences of discrimination may not impact depressive
symptoms through dopaminergic pathways, and instead are associated through alternative
pathways. Our results differ from findings in previous studies in which the Val158Met
polymorphism was reported to moderate associations between psychosocial stressors and
depressive symptoms.41,52,53 However, these studies differ from the present study as they
were conducted in mainly samples with European ancestry, and examined different
psychosocial stressors, such as adverse life events and experiences of childhood
trauma.41,52,53
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This study further strengthens the knowledge base about the impact of
experiences of ethnic discrimination on mental health, specifically on symptoms of
depression. This sample of Hispanic adults reported relatively few experiences of ethnic
discrimination, and relatively low levels of depressive symptoms. Despite this,
experiences of discrimination were predictive of increased depressive symptoms,
suggesting that this is an important risk factor for depressive symptoms that should be
considered in this population. Additionally, this study adds to the knowledge of how the
Val158Met polymorphism may influence depressive symptoms in Hispanic populations,
and presents preliminary findings identifying individuals who may be at higher risk for
depressive symptoms.
4.4.1

Strengths and Limitations

This study has several strengths and limitations that should be noted. First, the
sample size in this study was relatively small (N = 124) and reported experiences of
discrimination and depressive symptoms were low in this sample. To better understand
this phenomenon, and to verify our preliminary findings, larger studies with more
variance in discrimination experiences and depressive symptoms are needed.
Additionally, in the present study, the use of anti-depressant medication was unable to be
controlled for in the analysis due to lack of medication data for all participants. For the
participants who did have complete medication data (n = 102), no participants reported
anti-depressant medication use. Future research should aim to have complete medication
records for all participants as to be able to adjust analyses for the use of anti-depressant
medications.
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4.5

Conclusion
Experiences of ethnic discrimination are associated with increased depressive

symptoms in Hispanic adults, and findings from this study provide further evidence of
this relationship. The mechanisms underpinning this relationship remain unclear, as the
Val158Met polymorphism was not found to moderate the association between
experiences of discrimination and depressive symptoms. However, findings from this
study did reveal the Val158Met polymorphism to be an independent predictor of
depressive symptoms, with the Met allele associated with increased depressive
symptoms. These findings suggest that both experiences of discrimination and
Val158Met genotype may influence depression in Hispanic adults, which may place
certain individuals at higher risk than others for depression, and subsequently CVD.
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Table 4.1 Participant Characteristics (N = 124)

Age (years)

40.2 ± 9.3

Gender (male)

32 (25.8%)

Region of Origin
Mexico
Caribbean
Central America
South America

100 (80.7%)
3 (2.4%)
4 (3.2%)
17 (13.7%)

Marital status
Single, divorced, or widowed
Married or cohabitating

37 (29.8%)
87 (70.2%)

Financial status
Not enough to make ends meet
Enough or more than enough to make ends meet

26 (21.0%)
98 (79.0%)

Education level
High school or less
More than high school

86 (69.4%)
38 (30.6%)

Acculturation

20.9 ± 5.2

Experiences of discrimination

2.9 ± 5.1

Val158Met Polymorphism
Val/Val
Val/Met + Met/Met

48 (38.7%)
76 (61.3%)

Depressive Symptoms

2.7 ± 3.3

Values reported as either mean ± SD or n (%).
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Table 4.2 Summary of hierarchical multiple linear regression to examine moderating
effects of Val158Met genotype on associations between experiences of discrimination
and depressive symptoms
Variable

B

𝝱

95% CI for B

p
value

Block 1

Age

-0.071

-0.201

(-0.135, -0.008)

0.028

Gender (male)

0.959

0.127

(-0.415, 2.333)

0.170

0.378

0.052

(-0.900, 1.655)

0.559

0.674

0.083

(-0.772, 2.121)

0.358

-0.609

-0.085

(-1.943, 0.725)

0.368

Acculturation

-0.010

-0.016

(-0.131, 0.111)

0.871

Experiences of
discrimination

0.124

0.192

(0.010, 0.238)

0.034

Marital status
(single,
divorced,
widowed)
Financial
status
(enough or
more than
enough to
make ends
meet)
Education
level
(high school
or less)

Block 2

Age

-0.077

-0.217

(-0.140, -0.014)
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0.017

R

R2

R2
change

0.339

0.115

0.115

0.383

0.147

0.032

Table 4.2 continued
Gender

0.828

0.687

(-0.533, 2.189)

0.231

Marital status

0.187

0.026

(-1.086, 1.460)

0.772

Financial
status

0.443

0.055

(-1.001, 1.887)

0.544

Education
level

-0.602

-0.084

(-1.918, 0.714)

0.367

Acculturation

-0.023

-0.036

(-0.143, 0.097)

0.708

Experiences of
discrimination

0.146

0.224

(0.031, 0.260)

0.013

Val158Met
(Val/Val)

1.260

0.186

(0.055, 2.465)

0.041

Block 3

0.385

Age

-0.077

-0.217

(-0.140, -0.014)

0.017

Gender

0.824

0.109

(-0.543, 2.190)

0.235

Marital status

0.200

0.028

(-1.079, 1.479)

0.757

Financial
status

0.451

0.056

(-0.998, 1.901)

0.538

Education
level

-0.590

-0.082

(-1.912, 0.732)

0.379

Acculturation

-0.019

-0.030

(-0.141, 0.104)

0.764
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0.148

0.001

Table 4.2 continued
Experiences of
discrimination

0.170

0.260

(0.007, 0.332)

0.041

Val158Met

1.407

0.208

(0.005, 2.810)

0.049

Discrimination
* Val158Met

-0.048

-0.054

(-0.277, 0.182)

0.682
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CONCLUSION
5.1

Background and Purpose
The overall purpose of this dissertation was to examine associations between

psychosocial stressors and CVD risk factors, and the influence of genes on these
associations in populations burdened with significant cardiovascular health disparities.
This dissertation includes three original manuscripts. The first manuscript is a systematic
review of instruments that have been psychometrically tested and used to measure ethnic
discrimination is Hispanic adults. In the second paper, findings from a secondary analysis
of data conducted with a rural Kentucky population are reported. The purpose of the
second paper was to examine associations between anxiety and serum levels of CRP and
IL6, and the moderation of this relationship by genetic variants located on the CRP gene,
IL-6 gene, and IL-6R gene. In the final paper, results from a study conducted to examine
whether experiences of ethnic discrimination predicted depressive symptoms in Hispanic
adults, and to explore if a genetic variant on the COMT (catechol-o-methyltransferase)
gene moderated this relationship are reported.
Considering the high prevalence of CVD, and the high rates of mortality associated
with CVD,1 particularly in the rural Kentucky2 and Hispanic3 communities, prevention of
CVD remains a critical priority. However, in high-risk populations, CVD prevention
remains a major challenge. Although CVD risk is multifactorial and involves genetic,
behavioral, environmental, and psychosocial factors, CVD prevention efforts to date have
focused primarily on behavioral and environmental risk factors. Far less is understood
about how psychosocial factors, including psychosocial stressors, and genetic variants
affect CVD risk.4
72

Psychosocial stress is a type of stress that occurs when an individual’s environmental
demands tax or exceed the individual’s adaptive capabilities.5 Multiple factors are known
to influence CVD risk in rural and Hispanic populations, however, psychosocial stressors
may be particularly significant contributors to CVD risk. Examples of relevant
environmental stressors in rural and Hispanic adult populations include experiences of
discrimination, low socioeconomic status, and limited access to healthcare. Experiences
of these stressors lead to psychosocial stress, which has been associated with increased
physiological stress responses and psychological symptoms, which in turn, may further
increase CVD risk. It is of particular importance to examine psychosocial factors that
impact CVD risk in U.S. rural and Hispanic populations who experience unique
psychosocial risk factors that may further exacerbate CVD risk.2,3
This dissertation was guided by a conceptual framework that was based on the
“Pathways between Racism and Health” conceptual framework created by Paradies and
colleagues in 2013.6 The original model was based on the findings of a systematic review
and meta-analysis, and described multiple pathways through which racial discrimination
is associated with physical and mental health outcomes, including through psychological
stress processes.6 For the purposes of this dissertation, the framework was modified based
on existing literature which describe pathways between general psychosocial stressors
and physical and mental health outcomes (Figure 5.1). The modified framework presents
a pathway linking psychosocial stress to psychological symptoms and mental and
physical health outcomes and includes genetic variants as a potential moderator of the
association between psychosocial stressors and psychological symptoms.
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The purpose of this chapter is to summarize, synthesize, and discuss the findings of
the three studies in this dissertation. In this chapter is a discussion of how the outcomes
of these studies further the knowledge and the state of the science regarding stress, genes,
and CVD risk in populations suffering from cardiovascular health disparities. Lastly,
recommendations are made for practice and future research directions.

5.2

Summary of Findings
Chapter 2 of this dissertation is a systematic review of instruments measuring

ethnic discrimination that have been psychometrically tested and used with Hispanic
adult populations. The review study included 16 articles in which six measures of racial
and/or ethnic discrimination in Hispanic adults were described. In the majority of the
articles (n = 14) psychometric testing of the instrument was reported as part of the
findings from a larger study. Two articles were written specifically to report results of
validity and reliability testing of the instrument. In 10 of the articles, the instruments were
used in Hispanic-only samples, and in the six remaining articles, the instruments were
used in multi-ethnic samples which included portions of Hispanic adults. The instruments
varied in length, ranging from 6 to 70 items, and all instruments relied on self-report to
measure ethnic discrimination. Most instruments aimed to measure discrimination across
multiple settings (e.g., at work, at school, in public locations), but the instruments varied
in the timeframes in which they ask respondents to report experiences of ethnic
discrimination (e.g. past week, past year, lifetime). While all instruments were found to
be valid and reliable measures of ethnic discrimination, only two instruments had Spanish
language versions that were psychometrically tested. The availability of Spanish and
English language versions of the instrument, length, and the populations in which the
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instruments have been tested were considered. While evidence supports the reliability and
validity of each instrument, the Experiences of Discrimination (EOD) instrument has
been shown to be valid and reliable in both Spanish and English. Further, the EOD is a
concise instrument, limiting participant burden, while reliably and validly measuring
lifetime experiences of ethnic discrimination in Hispanic adults across 9 different
settings.7 These findings provide important guidance to the scientific community as they
can serve as a guide when selecting appropriate instruments to measure lifetime
experiences of ethnic discrimination.
Chapter 3 was a secondary analysis of data examining whether anxiety predicted
levels of systemic inflammation, and if three genetic variants associated with
inflammation moderated this relationship in a sample of rural Kentucky adults with two
or more CVD risk factors (N = 398). These variants assessed for moderation effect
included single nucleotide polymorphisms (SNPs) rs1205, located on the C-reactive
protein (CRP) gene,8 rs1800797 (Interleukin-6 (IL-6) gene),9 and rs4129267 (Interleukin6 Receptor (IL-6R) gene).10 Findings from this study indicated that anxiety was positively
associated with IL-6 protein levels. Based on results of the moderation analysis, this
association was significant only for individuals with the rs4129267 CC genotype, and not
for those with CT or TT genotypes, nor for the rs1205 or rs1800797 SNPs. These
findings suggest that there may be genotypic differences in individuals’ responses to
anxiety, which may place certain individuals at higher risk than others for inflammation,
and subsequently CVD. Although further research is needed to verify these findings,
results from this study add to the body of knowledge describing potential mechanism(s)
through which anxiety is associated with inflammation. Further, these findings provide
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preliminary insight into factors that may underlie the relationship between psychosocial
stress and CVD risk.
In Chapter 4, results of a study conducted to examine relationships between
lifetime experiences of ethnic discrimination, depressive symptoms, and genetic variants
associated with depressive symptoms are reported. This was a cross-sectional analysis of
data from 124 Hispanic adults at-risk for or with diagnosed CVD. Analyses were
conducted to determine whether there were significant associations between lifetime
experiences of ethnic discrimination and depressive symptoms or between Val158Met
polymorphism and depressive symptoms, and to explore the moderating effect of
Val158Met polymorphism on the association between discrimination and depressive
symptoms. The results of the analyses revealed that experiences of ethnic discrimination
and allelic variants of the Val158Met polymorphism were independent predictors of
depressive symptoms, with more experiences of ethnic discrimination and the Met allele
independently associated with increased depressive symptoms. Variants of the
Val158Met polymorphism did not moderate the association between experiences of
ethnic discrimination and depressive symptoms in this sample. This study is among the
first conducted to examine associations between ethnic discrimination, the Val158Met
polymorphism, and depressive symptoms in a Hispanic sample. Similar to the previous
study in Chapter 3, replication of this study is needed to verify the findings. However,
these preliminary findings provide a unique contribution to the growing body of scientific
knowledge regarding influences of genes on factors associated with CVD risk, such as
depressive symptoms. Further, the study provides a much-needed focus on genetic
influences on health outcomes in Hispanics, a population seldom included in genetic
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studies. Finally, findings from this study provide further evidence of the association
between experiences of discrimination and negative health outcomes.

5.3

Impact of Dissertation on the State of the Science
Cardiovascular disease remains the leading cause of death in the U.S., despite

ongoing prevention efforts.1 Nationally, it is estimated that nearly half of all adults aged
20 years and older have CVD.1 However, certain populations within the U.S. suffer
disproportionately from CVD, and have a higher CVD risk burden than other
populations. Both adults residing in rural Kentucky and Hispanic adults suffer higher
rates of CVD and have higher prevalence of CVD risk factors than the general
population.2,3,11-14 The increased risk for CVD seen in these two populations is further
compounded by the presence of unique psychosocial stressors which may increase CVD
risk in these populations. The findings from this dissertation further expand our
understanding of psychosocial stressors, including anxiety and experiences of
discrimination, and genetics as CVD risk factors in populations at increased risk for
CVD. Specifically, the outcomes of the studies 1) provide evidence of valid and reliable
instruments to measure ethnic discrimination experiences in Hispanic adults; 2) suggest
that the relationship between anxiety and systemic inflammation in rural Kentucky adults
is moderated by a genetic variant in an inflammatory pathway; and 3) indicate that
experiences of ethnic discrimination and a genetic variant associated with dopamine
degradation predict depressive symptoms in Hispanic adults.
In Chapter 2, I conducted a systematic review of the literature in which 16 articles
describing six measures of ethnic discrimination appropriate for use in Hispanic adult
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populations were identified. In Chapter 2, the validity and reliability of each instrument,
as well as considerations for their use, were discussed. Findings from this study highlight
the inconsistencies in the validity and reliability testing of these instruments with
Hispanic populations; some instruments completed psychometric testing with multiethnic and multi-racial samples and did not differentiate results by ethnic or racial subgroups, while others did conduct psychometric testing with entirely Hispanic samples.
Further, there is a lack of psychometric testing conducted to validate Spanish versions of
these instruments, which are necessary when used with Hispanic samples in the U.S, as
62% of Hispanics in the U.S. are bilingual, and nearly 40% primarily use Spanish.15 To
confirm the validity of these instruments for use in Hispanic populations, future validity
testing needs to be conducted with Hispanic-only samples, and both English and Spanish
versions need to undergo validation prior to use with Hispanic samples.
In Chapter 3, the relationship between anxiety and systemic inflammation, as well
as the possible moderation of this relationship by genetic variants associated with
inflammation were explored. Literature about the association between anxiety and
inflammation has been contradictory, with findings from some studies supporting this
relationship and others disputing it. Our findings did not support a relationship between
anxiety and systemic inflammation. The lack of consistent findings in regard to this
relationship suggests that additional factors may influence this relationship. Thus, three
SNPs associated with inflammation were examined as potential moderators. Of the three
SNPs, rs4129267 was the only SNP found to have a moderating effect, with the
association between anxiety and IL-6 significant only for those with a rs4129267 CC
genotype, and not those with a CT or TT genotype. This is consistent with the current
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knowledge about the pro-inflammatory properties associated with the T allele of the
rs419267 SNP.16-18 Our findings suggest that individuals with the CT or TT rs4129267
genotype may experience persistent elevated systemic inflammation regardless of anxiety
levels. Conversely, those with an rs4129267 CC genotype, which has not previously been
associated with increased systemic inflammation, may experience an increased
inflammatory response to stressors, such as anxiety. These findings add to the knowledge
about possible mechanism(s) through which anxiety is associated with systemic
inflammation. Additionally, these findings can guide future work aimed at identifying
individuals who are at higher risk than others for inflammation, and subsequently CVD,
based on genotypic differences identified through this study.
The findings described in Chapter 4 support the body of knowledge outlining the
negative health effects associated with experiences of discrimination. Although the
association between experiences of ethnic discrimination and depressive symptoms has
been previously illustrated, these findings add to the literature by providing evidence of
this relationship in an entirely Hispanic sample with diverse countries of origin. Further,
the findings from this study attempted to describe how experiences of discrimination
influence depressive symptoms through the examination of the Val158Met
polymorphism as a potential moderator of this relationship. While the Val158Met
polymorphism was not found to moderate the relationship between experiences of
discrimination and depressive symptoms, the Val158Met polymorphism was found to be
an independent predictor of depressive symptoms in this sample. These findings provide
a foundation for future work surrounding the biological mechanism(s) which may
underpin the association between discriminatory experiences and depressive symptoms in
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Hispanic adults. Additionally, our findings provide evidence supporting the association
between the Met allele and increased depressive symptoms, a relationship that has been
previously described in the literature. These findings suggest that there may be genotypic
differences in risk for depressive symptoms, which may place certain individuals at
higher risk than others for depressive symptoms, and subsequently CVD, than others.
Confirmation of these findings in future work could support interventions tailored based
on genotypic differences to ultimately improve CVD prevention efforts.
The findings from this dissertation support the need to identify and address
psychosocial stressors, which may influence CVD risk in populations that already bear a
high CVD risk burden. By beginning to identify specific stressors, such as experiences of
ethnic discrimination, and anxiety, as well as their interactions with genetic variants, such
as the rs419267 SNP, we can see that there are certain novel predictors that are associated
with increases in known CVD risk factors, including depressive symptoms and
inflammation. These findings may help to explain why certain populations are at higher
risk for CVD than other populations. Further, identification of these risk factors can help
to inform future CVD prevention efforts, and to ensure that interventions are tailored to
the populations of interest in order to increase efficacy of the interventions.

5.4

Recommendations for Practice and Research
This dissertation provides groundwork for identifying relevant psychosocial

stressors that influence CVD risk in at-risk populations. It is well documented that certain
populations suffer disproportionately from CVD. As such, the identification of novel
CVD risk factors, including psychosocial stressors specific to these populations, are key
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to better understanding cardiovascular health disparities, such as those seen in rural
Kentucky and Hispanic adults. Further research is needed to provide more robust
evidence of the associations between anxiety and inflammation and experiences of
discrimination and depressive symptoms. This future work should be conducted in large
samples with more variance in the levels of anxiety and experiences of discrimination
and should be able to adjust analyses for all relevant confounding factors. Additionally,
further research should aim to identify additional psychosocial stressors that are relevant
to the populations of interest.
It is also important that future research be conducted to investigate potential
interactions among and genetic influences on psychosocial and other CVD risk factors.
Expanding our knowledge about biological and genetic pathways that may affect CVD
risk will help to identify individuals and groups at the highest risk for CVD. Future
research examining genetic variants and CVD risk should be conducted in large samples,
in which comparisons could be made across homogenous sub-samples. It would also be
beneficial to use genetic ancestry markers to control for confounding. Further, future
research should examine other types of genetic variants and changes, such as DNA
methylation, and how these changes may alter CVD risk. Increasing our knowledge about
how genetic variants affect CVD risk can help to inform and guide tailoring of CVD
interventions so that those at highest risk for CVD receive more intensive intervention.
Upon identification of psychosocial stressors and genetic variants that may
influence CVD risk, targeted interventions should be created and tested for effectiveness.
Such interventions tailored to specific populations or to individuals within populations,
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can be developed to address the most relevant risk factors in order to increase
effectiveness of CVD prevention efforts.

5.5

Limitations
Although this dissertation has filled several important gaps in our knowledge of

how psychosocial stressors, genes, and the interaction between these influence CVD risk
in at-risk populations, some limitations of this work should be acknowledged. Primary
among these, Chapters 3 and 4 describe preliminary findings of associations between
CVD risk factors and genetic variants as well as moderating effects of these variants on
CVD risk. Study replication is needed to confirm the findings. Specific to the study in
which associations between depressive symptoms, experiences of discrimination, and
genotypic variations in Hispanics were examined, a larger study in which associations
could be examined in more homogenous groups such as populations representative of
specific countries-of-origin or genetic ancestry, will be more informative and is
recommended for future research.

5.6

Conclusions
Findings from this dissertation suggest that unique psychosocial stressors

influence CVD risk in populations known to suffer from cardiovascular health inequities.
Psychosocial stressors, in combination with genes and behavioral CVD risk factors, may
further increase the prevalence of CVD in rural Kentucky and Hispanic adults. Further
studies are needed to provide more robust evidence of these relationships, from which
interventions can be tailored to improve CVD prevention efforts in both of these
populations.
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Figure 5.1 Modified conceptual framework
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